```
=> e mayeresse yves/au
E1            9     MAYERES JEAN PIERRE/AU
E2           15     MAYERES P/AU
E3            5 --> MAYERESSE YVES/AU
E4            3     MAYEREZELL R/AU
E5            6     MAYERFELD D/AU
E6            1     MAYERFELD DONI/AU
E7            1     MAYERFELD P/AU
E8            2     MAYERFI Z/AU
E9            1     MAYERFIGGE A/AU
E10           2     MAYERFIGGE H/AU
E11           3     MAYERGI H A/AU
E12           4     MAYERGOIZ M/AU

=> s e3
L1            5 "MAYERESSE YVES"/AU

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2             5 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L2   ANSWER 1 OF 5  USPATFULL on STN
AN     2006:150980  USPATFULL
TI     Drying process
IN     Mayeresse, Yves, Rixensart, BELGIUM
PI     US 2006127415      A1   20060615
AI     US 2003-533462     A1   20031030 (10)
       WO 2003-EP12191         20031030
                               20060303  PCT 371 date
PRAI   GB 2002-25520       20021101
       GB 2002-25532       20021101
       GB 2002-25543       20021101
       GB 2003-17381       20030724
       GB 2003-17380       20030724
       GB 2003-17371       20030724
DT     Utility
FS     APPLICATION
LREP   SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US,
       UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US
CLMN   Number of Claims: 39
ECL    Exemplary Claim: 1
DRWN   1 Drawing Page(s)
LN.CNT 1284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to a method of drying biological and other
       labile samples so that they can be preserved as a highly viscous liquid.
       The method involves the steps of preparing a preservation sample by
       dissolving/suspending an active agent in a solution of a stabilising
       agent, subjecting the preservation sample to such temperature and
       pressure conditions that the preservation sample looses solvent by
       evaporation without freezing or bubbling to form a foam and removing
       solvent until the preservation sample dries to form a highly viscous
       liquid.

L2   ANSWER 2 OF 5  USPATFULL on STN
AN     2006:150979  USPATFULL
TI     Immunogenic Composition
IN     Mayeresse, Yves, Rixensart Brussels, BELGIUM
       Stephenne, Jean, Rixensart Brussels, BELGIUM
PA     Glaxosmithkline Biologicals S.A., Rixensart Brussels, BELGIUM, B-1330
       (non-U.S. corporation)
```

PI US 2006127414 A1 20060615
AI US 2003-533464 A1 20031030 (10)
WO 2003-EP12160 20031030
20060303 PCT 371 date
PRAI GB 2002-25520 20021101
GB 2002-25532 20021101
GB 2002-25543 20021101
GB 2003-17381 20030724
GB 2003-17380 20030724
GB 2003-17371 20030724
DT Utility
FS APPLICATION
LREP SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1796
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to immunogenic compositions comprising a dried solid or highly viscous liquid formulation of inactivated polio virus (IPV) and a stabilising agent wherein the IPV retains its antigenicity and/or immunogenicity. Methods of producing a dried formulation of IPV which retains its antigenicity/immunogenicity are described.

L2 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1194404 CAPLUS
DN 143:446917
TI Drying process for biological and other labile samples using a polyol stabilizing agent
IN Mayeresse, Yves
PA Glaxosmithkline Biologicals S. A., Belg.
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005105978	A2	20051110	WO 2005-EP4638	20050428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2004-9795 A 20040430
AB The present invention relates to a method of drying biol. and other labile samples so that they can be preserved as a highly viscous liquid The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample looses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid The stabilizing solution comprises a glass forming polyol and a second component which decreases the flow rate of the highly viscous liquid formed by the method. For example, inactivated

poliovirus (IPV) was resuspended in an aqueous solution with 2.5% sucrose, 10% sucrose or 10% trehalose as the stabilizing agent and dried at 15° and pressure of 35 mbar. As water evaporated from the sample, the temperature dropped to 4° but towards the end of the 2 h, the temperature returned to 15° as the rate of evaporation slowed. No bubbling or foam formation occurred under these conditions. The pressure was then reduced further to 0.1 mbar and these conditions were maintained for 16 h more in the first two expts. and for 10 h more in the third experiment The samples were reconstituted in water and an ELISA was used to assess the degree of antigen retention. The levels of type 3 IPV antigen retention compares very favorably with the freeze drying results.

L2 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:387292 CAPLUS
DN 140:388255
TI Drying process for biologicals and labile samples to be preserved as highly viscous liquids
IN Mayeresse, Yves
PA Glaxosmithkline Biologicals S.A., Belg.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039417	A2	20040513	WO 2003-EP12191	20031030
	WO 2004039417	A3	20041216		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503946	AA	20040513	CA 2003-2503946	20031030
	AU 2003287980	A1	20040525	AU 2003-287980	20031030
	EP 1556477	A2	20050727	EP 2003-779829	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015733	A	20050906	BR 2003-15733	20031030
	CN 1732257	A	20060208	CN 2003-80107869	20031030
	JP 2006504801	T2	20060209	JP 2005-501819	20031030
	NO 2005001998	A	20050624	NO 2005-1998	20050425
	US 2006127415	A1	20060615	US 2006-533462	20060303
PRAI	GB 2002-25520	A	20021101		
	GB 2002-25532	A	20021101		
	GB 2002-25543	A	20021101		
	GB 2003-17371	A	20030724		
	GB 2003-17380	A	20030724		
	GB 2003-17381	A	20030724		
	WO 2003-EP12191	W	20031030		

AB The present invention relates to a method of drying biol. and other labile samples so that they can be preserved as a highly viscous liquid The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample loses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid IPV (inactivated polio virus) was resuspended in an aqueous solution with 10 % sucrose or 10 % trehalose as the

stabilizing agent. The samples were put into siliconized vials which were placed into a Heto Drywinner 8-85 freeze-dryer and the temperature was set to 15°. The pressure was initially reduced to 35 mBars to degas the sample. After 10 min, the pressure was further reduced to 8 mBars and was kept at this level for two hours. As water evaporated from the sample, the temperature dropped to 4° but towards the end of the two hours, the temperature returned to 15° as the rate of evaporation slowed. No bubbling or foam formation occurred under these conditions. The pressure was then reduced further to 0.1 mBars and these conditions were maintained for 16 h more in the first two expts. and for 10 h more in the third experiment IPV which had been dried by this method could be stored at 4° for at least 9 mo without loss of antigenicity.

L2 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:387280 CAPLUS
DN 140:380587
TI Immunogenic composition
IN Mayeresse, Yves; Stephenne, Jean
PA Glaxosmithkline Biologicals S.A., Belg.
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039399	A1	20040513	WO 2003-EP12160	20031030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503871	AA	20040513	CA 2003-2503871	20031030
	AU 2003278166	A1	20040525	AU 2003-278166	20031030
	BR 2003015767	A	20050906	BR 2003-15767	20031030
	EP 1575612	A1	20050921	EP 2003-769479	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1732257	A	20060208	CN 2003-80107869	20031030
	CN 1735430	A	20060215	CN 2003-80108184	20031030
	JP 2006512406	T2	20060413	JP 2005-501818	20031030
	NO 2005002010	A	20050624	NO 2005-2010	20050425
	US 2006127414	A1	20060615	US 2006-533464	20060303
PRAI	GB 2002-25520	A	20021101		
	GB 2002-25532	A	20021101		
	GB 2002-25543	A	20021101		
	GB 2003-17371	A	20030724		
	GB 2003-17380	A	20030724		
	GB 2003-17381	A	20030724		
	WO 2003-EP12160	W	20031030		

AB The present invention relates to immunogenic compns. comprising a dried solid or highly viscous liquid formulation of inactivated polio virus (IPV) and a stabilizing agent wherein the IPV retains its antigenicity and/or immunogenicity. Methods of producing a dried formulation of IPV which retains its antigenicity/immunogenicity are described.

=> e franks felix/au
E1 1 FRANKS F T/AU

```
E2            8     FRANKS FARAH JUDITH/AU
E3          243 --> FRANKS FELIX/AU
E4            1     FRANKS FIONA/AU
E5            6     FRANKS FIONA M/AU
E6            1     FRANKS FRANCES/AU
E7            1     FRANKS FRED B/AU
E8            2     FRANKS FREDERICK/AU
E9           22     FRANKS G/AU
E10           1     FRANKS G B/AU
E11           6     FRANKS G C/AU
E12           2     FRANKS G D/AU

=> s e3 and preserv? and (stabiliz? agent?)
L3            0 "FRANKS FELIX"/AU AND PRESERV? AND (STABILIZ? AGENT?)

=> s e3 and preserv?
L4           20 "FRANKS FELIX"/AU AND PRESERV?

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           20 DUP REM L4 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 20  USPATFULL on STN
AN     2005:124164  USPATFULL
TI     Storage of materials
IN     Franks, Felix, Cambridge, UNITED KINGDOM
       Hatley, Ross Henry, Cambridge, UNITED KINGDOM
       Mathias, Sheila Frances, Swaffham, UNITED KINGDOM
PI     US 2005106553      A1   20050519
AI     US 2004-877047     A1   20040625 (10)
RLI    Continuation of Ser. No. US 2002-72604, filed on 8 Feb 2002, GRANTED,
       Pat. No. US 6825031 Continuation of Ser. No. US 1999-317779, filed on 24
       May 1999, GRANTED, Pat. No. US 6426210 Continuation of Ser. No. US
       1994-241457, filed on 11 May 1994, GRANTED, Pat. No. US 5928469
       Continuation of Ser. No. US 1992-902838, filed on 23 Jun 1992, ABANDONED
PRAI   GB 1991-13798       19910626
       GB 1992-7839        19920409
DT     Utility
FS     APPLICATION
LREP   NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070, US
CLMN   Number of Claims: 14
ECL    Exemplary Claim: 1
DRWN   1 Drawing Page(s)
LN.CNT 749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Materials which are not themselves storage-stable at room temperature
       are made suitable for storage by mixing them with a carrier substance
       and spray drying the resulting mixture so as to form particles
       containing both the material and the carrier substance in which the
       carrier substance is in an amorphous, i.e. glassy or rubbery, state.
       Formation of such a composition greatly enhances stability. The material
       stored may be a biological material such as an enzyme, the components of
       a chemical reaction such as reagents for carrying out an assay, or even
       viable biological cells.

L5   ANSWER 2 OF 20  USPATFULL on STN
AN     2004:8949  USPATFULL
TI     Storage of materials
IN     Franks, Felix, Cambridge, UNITED KINGDOM
       Hatley, Ross H. M., Cambridge, UNITED KINGDOM
PA     Nektar Therapeutics, San Carlos, CA, United States (U.S. corporation)
```

PI US 38385 E1 20040113
US 5098893 19920324 (Original)
AI US 2001-939688 20010828 (9)
US 1990-479939 19900212 (Original)
RLI Continuation of Ser. No. US 1999-270791, filed on 17 Mar 1999, now patented, Pat. No. US 37872
PRAI GB 1989-3593 19890216
DT Reissue
FS GRANTED
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Cagan, Felissa H., Neifeld, Richard A., Evans, Susan T.
CLMN Number of Claims: 59
ECL Exemplary Claim: 46
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

L5 ANSWER 3 OF 20 USPATFULL on STN
AN 2003:57896 USPATFULL
TI Storage of materials
IN Franks, Felix, Cambridge, UNITED KINGDOM
Hatley, Ross Henry, Cambridge, UNITED KINGDOM
Mathias, Sheila Frances, Swaffham, UNITED KINGDOM
PI US 2003040462 A1 20030227
US 6825031 B2 20041130
AI US 2002-72604 A1 20020208 (10)
RLI Continuation of Ser. No. US 1999-317779, filed on 24 May 1999, GRANTED, Pat. No. US 6426210 Continuation of Ser. No. US 1994-241457, filed on 11 May 1994, GRANTED, Pat. No. US 5928469 Continuation of Ser. No. US 1992-902838, filed on 23 Jun 1992, ABANDONED
PRAI GB 1991-13798 19910626
GB 1992-7839 19920409
DT Utility
FS APPLICATION
LREP INHALE THERAPEUTIC SYSTEMS, INC, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 766
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials which are not themselves storage-stable at room temperature are made suitable for storage by mixing them with a carrier substance and spray drying the resulting mixture so as to form particles containing both the material and the carrier substance in which the carrier substance is in an amorphous, i.e. glassy or rubbery, state. Formation of such a composition greatly enhances stability. The material stored may be a biological material such as an enzyme, the components of a chemical reaction such as reagents for carrying out an assay, or even viable biological cells.

L5 ANSWER 4 OF 20 USPATFULL on STN
AN 2002:188242 USPATFULL
TI Storage of materials
IN Franks, Felix, Cambridge, UNITED KINGDOM
Hatley, Ross Henry, Cambridge, UNITED KINGDOM
Mathias, Sheila Frances, Swaffham, UNITED KINGDOM
PA Inhale Therapeutic Systems, Inc., San Carlos, CA, United States (U.S. corporation)

PI US 6426210 B1 20020730
AI US 1999-317779 19990524 (9)
RLI Continuation of Ser. No. US 1994-241457, filed on 11 May 1994, now patented, Pat. No. US 5928469
PRAI GB 1991-13798 19910626
GB 1992-7839 19920409
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prats, Francisco; Assistant Examiner: Coe, Susan D.
LREP Evans, Susan T., Cagan, Felissa H., Hurst, Stephen L.
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 977
AB Materials which are not themselves storage-stable at room temperature are made suitable for storage by mixing them with a carrier substance and spray drying the resulting mixture so as to form particles containing both the material and the carrier substance in which the carrier substance is in an amorphous, i.e. glassy or rubbery, state. Formation of such a composition greatly enhances stability. The material stored may be a biological material such as an enzyme, the components of a chemical reaction such as reagents for carrying out an assay, or even viable biological cells.

L5 ANSWER 5 OF 20 USPATFULL on STN
AN 2002:261057 USPATFULL
TI Storage of materials
IN Franks, Felix, Cambridge, UNITED KINGDOM
Hatley, Ross H. M., Hardwick, UNITED KINGDOM
PA Inhale Therapeutics Systems, Inc., San Carlos, CA, United States (U.S. corporation)
PI US 37872 E1 20021008
US 5098893 19920324 (Original)
AI US 1999-270791 19990317 (9)
US 1990-479939 19900212 (Original)
PRAI GB 1989-3593 19890216
DT Reissue
FS GRANTED
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Cagen, Felissa H., Neifeld, Richard A., Evans, Susan T.
CLMN Number of Claims: 94
ECL Exemplary Claim: 18
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

L5 ANSWER 6 OF 20 MEDLINE on STN
AN 2004112451 IN-PROCESS
DN PubMed ID: 15002619
TI Current topics on sample preservation. A report on the progress of the ESA Topical Team. Preservation of fixed and non-fixed samples during space experimentation.
AU Medina Francisco Javier; Cogoli Augusto; Franks Felix; Marco Roberto; Marthy Hans Jurg; Martin-Pascual Carlos; Kraemer Jutta; Pastor Miquel
CS Coordinator of the Topical Team, Centro de Investigaciones Biologicas (CSIC), Madrid, Spain.. fjmedina@cib.csic.es
SO Journal of gravitational physiology : a journal of the International Society for Gravitational Physiology, (2002 Jul) Vol. 9, No. 1, pp.

P371-2.
Journal code: 9437868. ISSN: 1077-9248.
Report No.: NASA-00030279.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Space Life Sciences
ED Entered STN: 9 Mar 2004
Last Updated on STN: 19 Dec 2004
AB The existence of preservation problems is one of the most important consequences of Space Biological Research. The Topical Team is critically analyzing the currently performed procedures and is establishing the bases for a recommendation on new procedures, capable of overcoming the present constraints.

L5 ANSWER 7 OF 20 USPATFULL on STN
AN 1999:84820 USPATFULL
TI Process for storage of materials
IN Franks, Felix, Cambridge, United Kingdom
Hatley, Ross Henry, Cambridge, United Kingdom
Mathias, Sheila Frances, Swaffham, United Kingdom
PA Inhale Therapeutic Systems, San Carlos, CA, United States (U.S. corporation)
PI US 5928469 19990727
AI US 1994-241457 19940511 (8)
RLI Continuation of Ser. No. US 1992-902838, filed on 23 Jun 1992, now abandoned
PRAI GB 1991-13798 19910626
GB 1992-7839 19920409
DT Utility
FS Granted
EXNAM Primary Examiner: Caldarola, Glenn; Assistant Examiner: Preisch, Nadine
LREP Cooley Godward LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 833
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials which are not themselves storage-stable at room temperature are made suitable for storage by mixing them with a carrier substance and spray drying the resulting mixture so as to form particles containing both the material and the carrier substance in which the carrier substance is in an amorphous, i.e. glassy or rubbery, state. Formation of such a composition greatly enhances stability. The material stored may be a biological material such as an enzyme, the components of a chemical reaction such as reagents for carrying out an assay, or even viable biological cells.

L5 ANSWER 8 OF 20 USPATFULL on STN
AN 92:23177 USPATFULL
TI Storage of materials
IN Franks, Felix, Cambridge, England
Hatley, Ross H. M., Hardwick, England
PA Pafra Limited, Basildon, England (non-U.S. corporation)
PI US 5098893 19920324
AI US 1990-479939 19900212 (7)
PRAI GB 1989-3593 19890216
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Abelman, Frayne & Schwab
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

L5 ANSWER 9 OF 20 USPATFULL on STN
AN 89:74125 USPATFULL
TI Preservation by cold storage
IN Franks, Felix, 7, Wootton Way, Cambridge CB3 9LX, England
PI US 4863865 19890905
AI US 1988-213517 19880628 (7)
RLI Continuation of Ser. No. US 1984-644505, filed on 24 Aug 1984, now abandoned
PRAI GB 1983-23094 19830826
DT Utility
FS Granted
EXNAM Primary Examiner: Weimar, Elizabeth C.
LREP Abelman Frayne Rezac & Schwab
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 705
AB Material which contains water, or is accompanied by an aqueous phase, notably biological cells, cell components or cell aggregates, or differentiated biological tissue is preserved by dispersion in an oil medium and under-cooling the dispersion, preferably to a temperature in the range -20° C. to -40° C. The oil medium is characterized by the absence of surfactant which can catalyze ice formation and is an immobile gel at the storage temperature. The preferred oil 10 medium is paraffin oil, or oil plus paraffin wax.

L5 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:217820 CAPLUS
DN 108:217820
TI The stabilization of labile biochemicals by undercooling
AU Hatley, Ross H. M.; Franks, Felix; Mathias, Sheila F.
CS Biopreserv. Div., Pafra Ltd., Cambridge, CB4 4GG, UK
SO Process Biochemistry (Rickmansworth, United Kingdom) (1987), 22(6), 169-72
CODEN: PRBCAP; ISSN: 0032-9592
DT Journal; General Review
LA English
AB A review with 26 refs. on the problems relating to the stabilization of isolated biochems., with special emphasis on proteins. A novel process for the preparation of products with long shelf-lives is described. It relies on undercooling, as distinct from freezing, and does not require the use of protectant additives. Isolated proteins can be formulated to any desired concentration and can be stored in a freezer (-12 or -20°) for extended periods without loss of activity.

L5 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:570762 CAPLUS
DN 105:170762
TI Subzero-temperature preservation of reactive fluids in the undercooled state. II. The effect on the oxidation of ascorbic acid of freeze concentration and undercooling
AU Hatley, Ross H. M.; Franks, Felix; Day, Hazel
CS Biopres. Div., Pafra Ltd., Cambridge, CB4 4GG, UK
SO Biophysical Chemistry (1986), 24(2), 187-92
CODEN: BICIAZ; ISSN: 0301-4622
DT Journal
LA English

AB The rate of oxidation of ascorbic acid [50-81-7] has been measured in both frozen and undercooled solns. A new interpretation is advanced for changes in the rate of ascorbic acid oxidation in freeze-concentrated solns. The results obtained with undercooled solns. indicate a rate reduction in line with that predicted by the Arrhenius equation. It is also demonstrated that undercooling provides a method for greatly extending the shelf life of reactive fluids.

L5 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:503391 CAPLUS
DN 105:103391
TI Subzero-temperature preservation of reactive fluids in the undercooled state. I. The reduction of potassium ferricyanide by potassium cyanide
AU Hatley, Ross H. M.; Franks, Felix; Day, Hazel; Byth, Barbara
CS Biopreserv. Div., Pafra Ltd., Cambridge, CB4 4GG, UK
SO Biophysical Chemistry (1986), 24(1), 41-6
CODEN: BICIAZ; ISSN: 0301-4622
DT Journal
LA English
AB The reduction of K3Fe(CN)6 by KCN was studied at <0° in both the undercooled and the frozen state. The pseudo-1st-order rate consts. calculated differ greatly from those in previous reports. A high degree of freeze concentration and supersatn. in frozen bulk solns. occurs. Undercooled preservation provides a useful method for the long-term storage of reactive mixts.

L5 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:782992 CAPLUS
TI Preservation by refrigeration
IN Franks, Felix
PA UK
SO Eur. Pat. Appl., No pp. given
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 136030	A2	19850403	EP 1984-305524	19840814
	EP 136030	A3	19850522		
	EP 136030	B1	19880720		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 35764	E	19880815	AT 1984-305524	19840814
	DK 8403985	A	19850227	DK 1984-3985	19840820
	AU 8432228	A1	19850228	AU 1984-32228	19840821
	AU 570996	B2	19880331		
	JP 60105601	A2	19850611	JP 1984-177376	19840824
	IL 72766	A1	19880531	IL 1984-72766	19840824
	US 4863865	A	19890905	US 1988-213517	19880628
PRAI	GB 1983-23094	A	19830826		
	EP 1984-305524	A	19840814		
	US 1984-644505	A1	19840824		

AB Unavailable

L5 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:207093 CAPLUS
DN 100:207093
TI Nucleation and growth of ice in deeply undercooled erythrocytes
AU Mathias, Sheila F.; Franks, Felix; Trafford, Kay
CS Dep. Bot., Univ. Cambridge, Cambridge, CB2 3EA, UK
SO Cryobiology (1984), 21(2), 123-32
CODEN: CRYBAS; ISSN: 0011-2240

DT Journal
LA English
AB Previous studies of the mechanism of freezing of erythrocytes in the absence of intracellular ice have been extended to define the catalytic sites responsible for promoting nucleation. The following aspects were investigated: (1) the freeze propagation between undercooled erythrocytes, (2) the nucleation of ice in undercooled erythrocyte ghosts, and (3) the freezing behavior of undercooled Hb solns. The main findings were: (1) no cross-nucleation occurred between individual cells packed within the same emulsified H2O droplet; (2) the differential scanning calorimetric power-time curves of intact cells and ghosts were identical, indicating that Hb does not affect ice nucleation; (3) the nucleation temperature of ice in an aqueous solution of Hb (isolated from the cells) was substantially lower than that for the same solution when contained in the intact cell; and (4) the 3-fold freeze concentration which accompanies the freezing of a 25% Hb solution does not cause denaturation of the protein.

L5 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:578379 CAPLUS
DN 97:178379
TI Preservation of cells
IN Franks, Felix
PA BOC Ltd., UK
SO Brit. UK Pat. Appl., 5 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2091534	A	19820804	GB 1981-37165	19811209
	GB 2091534	B2	19840627		
	AU 8178357	A1	19820617	AU 1981-78357	19811208
	DE 3148551	A1	19820923	DE 1981-3148551	19811208
	DE 3148551	C2	19910529		
PRAI	GB 1980-39429	A	19801209		

AB Plant or animal cells are preserved without the use of cryoprotectants by forming a water-in-oil emulsion from an aqueous suspension of cells and a nontoxic hydrophobic liquid (the oil), reducing the temperature of the emulsion to freeze intracellular water (-25 to -35°), and storing the emulsion at -70° or lower. The oil, such as silicone oil or glycerides, does not contact the cells which remain suspended in droplets of aqueous growth medium. An emulsifier, e.g., sorbitan tristearate, may be used to form the emulsion. Thus, soybean cells were preserved by adding a wet cell pellet to a portion of UV-sterilized silicone oil containing sorbitan tristearate which had been homogenized in the presence of cell medium. Aliquots of the cell-containing emulsion were transferred to sterile plastic tubes and cooled at <1°/min to -28°, then frozen to -90° in a deep freeze and then to -196° in liquid N. After 1 wk, the cells were thawed, removed from the emulsion, and showed >60% survival. The method also is useful for, e.g., erythrocytes and leukocytes.

L5 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:617270 CAPLUS
DN 95:217270
TI The use of high molecular weight polymers in the cryofixation of cells and tissues for ultrastructural and analytical studies
AU Echlin, Patrick; Franks, Felix; Saubermann, Albert; Lai, Clifford; Skaer, Helen

CS Bot. Sch., Univ. Cambridge, Cambridge, UK
SO Electron Microsc., Proc. Eur. Congr., 7th (1980), Volume 2, 714-15. Editor(s): Brederoo, P.; De Priester, W. Publisher: Seventh Eur. Congr. Electron Microsc. Found., Leiden, Neth.
CODEN: 46OAAU
DT Conference
LA English
AB Frozen-hydrated bulk tissue and frozen sections of Duckweed were cryofixed in polyvinylpyrrolidone (mol. weight 70,000) or hydroxymethyl-starch (mol. weight 450,000) prior to anal. at low temps. in the scanning electron microscope. With both of these high-mol.-weight water-soluble polymers, structural preservation was good.

L5 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:18688 CAPLUS
DN 90:18688
TI Nonpenetrating polymeric cryofixatives for ultrastructural and analytical studies of biological tissues
AU Skaer, Helen Le B.; Franks, Felix; Echlin, Patrick
CS Dep. Zool., Univ. Cambridge, Cambridge, UK
SO Cryobiology (1978), 15(5), 589-602
CODEN: CRYBAS; ISSN: 0011-2240
DT Journal
LA English
AB Existing freezing methods for biol. tissues, either for storing living material or for ultrastructural observation, are hampered by various limitations, such as small samples (spray-freezing) or the introduction of physiol. and(or) cytol. alterations (incubation in DMSO or glycerol, high pressure freezing). Therefore, the possibility of using aqueous polymer solns. as extracellular cryofixative media was investigated, the basis of structural preservation being the capacity of relatively dilute solns. to vitrify under quench cooling conditions. Evidence is presented to show that 2 such polymers, polyvinylpyrrolidone and (hydroxyethyl)starch, control, or even inhibit, intracellular freezing in a wide variety of quench-cooled tissue samples. The effects of these polymers on the physiol. of tissues from a range of different organisms were assessed by microscopy, electrophysiol., and secretion studies. At the concns. necessary to ensure vitrification, the polymer solns. cause only slight perturbations of the normal functioning of the cells studied. The special application of these studies to freeze-fracture and scanning electron microscopy is discussed.

L5 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:402693 CAPLUS
DN 89:2693
TI Polymeric cryoprotectants in the preservation of biological ultrastructure. III. Morphological aspects
AU Skaer, Helen le B.; Franks, Felix; Asquith, M. H.; Echlin, Patrick
CS Dep. Zool., Univ. Cambridge, Cambridge, UK
SO Journal of Microscopy (Oxford, United Kingdom) (1977), 110(3), 257-70
CODEN: JMICAR; ISSN: 0022-2720
DT Journal
LA English
AB Two high-mol.-weight polymers, poly(vinylpyrrolidinone) and hydroxyethyl starch, were used as cryoprotectants for preparing specimens to be freeze-fractured. Solns. of 25% suppress the formation of intracellular ice in single cells and tissue blocks from both plants and animals to the extent that fine structural details of the cell can be elucidated. The mode of action of these cryoprotectants, together with the structures they reveal and the peculiar advantages attached to their use, is discussed.

L5 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:166351 CAPLUS

DN 88:166351
TI Polymeric cryoprotectants in the preservation of biological ultrastructure. II. Physiological effects
AU Echlin, Patrick; Skaer, Helen le B.; Gardiner, B. O. C.; Franks, Felix; Asquith, M. H.
CS Bot. Sch., Univ. Cambridge, Cambridge, UK
SO Journal of Microscopy (Oxford, United Kingdom) (1977), 110(3), 239-55
CODEN: JMICAR; ISSN: 0022-2720
DT Journal
LA English
AB The physiol. effects of poly(vinylpyrrolidone), hydroxyethyl starch, and dextran nonpenetrating cryoprotective agents on 16 different plant and animal cells are determined When used in concns. at which they are effective in preventing ice-crystal formation, the cryoprotectants generally have lower toxicity to cells and tissue than similar concns. of glycerol. The relatively low toxicity of the cryoprotectants suggests their use in morphol. and anal. studies.

L5 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:170627 CAPLUS
DN 88:170627
TI Polymeric cryoprotectants in the preservation of biological ultrastructure. I. Low temperature states of aqueous solutions of hydrophilic polymers
AU Franks, Felix; Asquith, M. H.; Hammond, Catherine C.; Skaer, Helen le B.; Echlin, Patrick
CS Unilever Res. Lab., Colworth/Welwyn, UK
SO Journal of Microscopy (Oxford, United Kingdom) (1977), 110(3), 223-38
CODEN: JMICAR; ISSN: 0022-2720
DT Journal
LA English
AB The solid states formed by vitrified and frozen aqueous solns. of some hydrophilic polymers, which are useful as biol. cryoprotectants, were studied by differential scanning calorimetry and freeze fracture electron microscopy. Glass transitions, devitrification, recrystn., and melting behavior were established for aqueous solns. of poly(vinylpyrrolidone) [9003-39-8], hydroxyethyl starch [9005-27-0], and dextran [9004-54-0]. The vitrified polymer solns. exhibit a characteristic microspherical morphol. which is not induced by the quenching cooling process but is an inherent feature of the solns. themselves.

```
=> e roser bruce j/au
E1            1     ROSER BERNARD S/AU
E2           23     ROSER BRUCE/AU
E3           43 --> ROSER BRUCE J/AU
E4           45     ROSER BRUCE JOSEPH/AU
E5            1     ROSER BRUCE JOSPEH/AU
E6           22     ROSER C/AU
E7            1     ROSER C A/AU
E8            4     ROSER C E/AU
E9            1     ROSER C F/AU
E10           1     ROSER C L F/AU
E11           2     ROSER CARL A/AU
E12           2     ROSER CAROLA/AU

=> s e2-e5 and preserv?
L6           25 ("ROSER BRUCE"/AU OR "ROSER BRUCE J"/AU OR "ROSER BRUCE JOSEPH"/
                AU OR "ROSER BRUCE JOSPEH"/AU) AND PRESERV?

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7            24 DUP REM L6 (1 DUPLICATE REMOVED)
```

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1117883 CAPLUS
DN 143:373398
TI Liquids containing suspended water soluble glassy particles
IN Roser, Bruce Joseph
PA Cambridge Biostability Limited, UK
SO Brit. UK Pat. Appl., 13 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2413075	A1	20051019	GB 2005-4501	20050307
WO 2005099669	A1	20051027	WO 2005-GB50050	20050413

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2004-8199 A 20040413
GB 2005-4501 A 20050307
OS MARPAT 143:373398
AB A pharmaceutical composition comprising a biol. active agent preserved in particulate form, in particular a glass or amorphous particle, such as a sugar, a metal carboxylate, an amino acid or calcium phosphate, wherein the particles are suspended in at least one of a hydrofluoroether, a perfluoroether, a hydrofluoroamine, a perfluoroamine, a hydrofluorothioether, a perfluorothioether, a hydrofluoropolyether or a perfluoropolyether. The use of such fluorinated liquid media overcomes the problem of aggregation of particles and also is environmentally friendly.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 24 USPATFULL on STN
AN 2005:221479 USPATFULL
TI Dried blood factor composition comprising trehalose
IN Roser, Bruce Joseph, Cambridgeshire, UNITED KINGDOM
PA Quadrant Drug Delivery Limited, Ruddington, UNITED KINGDOM, NG11 6JS (non-U.S. corporation)
PI US 2005192216 A1 20050901
AI US 2003-658219 A1 20030908 (10)
RLI Continuation of Ser. No. US 2001-888734, filed on 25 Jun 2001, PENDING Continuation of Ser. No. US 1998-875796, filed on 30 Oct 1998, GRANTED, Pat. No. US 6649386 A 371 of International Ser. No. WO 1996-GB119, filed on 19 Jan 1996
PRAI GB 1995-1040 19950119
DT Utility
FS APPLICATION
LREP David R. Saliwanchik, Saliwanchik, Lloyd & Saliwanchik, A Professional, Association, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL, 32606, US
CLMN Number of Claims: 14

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.

L7 ANSWER 3 OF 24 USPATFULL on STN
AN 2005:214582 USPATFULL
TI Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
IN Roser, Bruce, Cambridge, UNITED KINGDOM
Gribbon, Enda Martin, Cambridge, UNITED KINGDOM
PA Elan Drug Delivery Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)
PI US 2005186254 A1 20050825
AI US 2005-81356 A1 20050315 (11)
RLI Continuation of Ser. No. US 1997-923783, filed on 4 Sep 1997, PENDING
Continuation of Ser. No. US 1995-486043, filed on 7 Jun 1995, ABANDONED
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-77
DRWN 6 Drawing Page(s)
LN.CNT 923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

L7 ANSWER 4 OF 24 USPATFULL on STN
AN 2005:118260 USPATFULL
TI Dried blood factor composition comprising trehalose
IN Roser, Bruce Joseph, Cambridgeshire, UNITED KINGDOM
PA Quadrant Drug Delivery Limited, Ruddington, UNITED KINGDOM (non-U.S. corporation)
PI US 2005101533 A1 20050512
AI US 2003-679723 A1 20031006 (10)
RLI Continuation of Ser. No. US 2003-658219, filed on 8 Sep 2003, PENDING
Continuation of Ser. No. US 2001-888734, filed on 25 Jun 2001, PENDING
Continuation of Ser. No. US 1998-875796, filed on 30 Oct 1998, GRANTED, Pat. No. US 6649386 A 371 of International Ser. No. WO 1996-GB119, filed on 19 Jan 1996
PRAI GB 1995-1040 19950119
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332, US
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.

L7 ANSWER 5 OF 24 USPATFULL on STN
AN 2005:288981 USPATFULL
TI Method for stably incorporating substances within dry, foamed glass matrices

IN Roser, Bruce, Cambridge, UNITED KINGDOM
Gribbon, Enda Martin, Cambridge, UNITED KINGDOM
PA Elan Drug Delivery Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)
PI US 6964771 B1 20051115
AI US 1997-923783 19970904 (8)
RLI Continuation of Ser. No. US 1995-486043, filed on 7 Jun 1995, PENDING
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saucier, Sandra E.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

L7 ANSWER 6 OF 24 USPATFULL on STN
AN 2004:172492 USPATFULL
TI Dried blood factor composition comprising trehalose
IN Roser, Bruce Joseph, Cambridgeshire, UNITED KINGDOM
PA Quadrant Drug Delivery Limited, Ruddington, UNITED KINGDOM (non-U.S. corporation)
PI US 2004132656 A1 20040708
AI US 2003-681948 A1 20031008 (10)
RLI Continuation of Ser. No. US 2003-679723, filed on 6 Oct 2003, PENDING
Continuation of Ser. No. US 2003-658219, filed on 8 Sep 2003, PENDING
Continuation of Ser. No. US 2001-888734, filed on 25 Jun 2001, PENDING
Continuation of Ser. No. US 1998-875796, filed on 30 Oct 1998, GRANTED, Pat. No. US 6649386 A 371 of International Ser. No. WO 1996-GB119, filed on 19 Jan 1996, UNKNOWN
PRAI GB 1995-1040 19950119
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.

L7 ANSWER 7 OF 24 USPATFULL on STN
AN 2003:166044 USPATFULL
TI Methods of preserving prokaryotic cells and compositions obtained thereby
IN Tunnacliffe, Alan G., Horningsea, UNITED KINGDOM
Welsh, David T., Stanley, UNITED KINGDOM
Roser, Bruce J., Cambridge, UNITED KINGDOM
Dhaliwal, Kamaljit S., Hitchin, UNITED KINGDOM
Colaco, Camilo, Cambridge, UNITED KINGDOM
PI US 2003113900 A1 20030619
AI US 2002-215060 A1 20020807 (10)
RLI Continuation of Ser. No. US 1997-985343, filed on 4 Dec 1997, GRANTED, Pat. No. US 6468782
PRAI US 1996-32423P 19961205 (60)
DT Utility

FS APPLICATION
LREP Madeline I. Johnston, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1646
AB This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.

L7 ANSWER 8 OF 24 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2002:622065 BIOSIS
DN PREV200200622065
TI Methods of preserving prokaryotic cells and compositions obtained thereby.
AU Tunnacliffe, Alan G. [Inventor, Reprint author]; Welsh, David T. [Inventor]; Roser, Bruce J. [Inventor]; Dhaliwal, Kamaljit S. [Inventor]; Colaco, Camilo Anthony Leo Selwyn [Inventor]
CS Horningsea, UK
ASSIGNEE: Quadrant Healthcare (UK) Limited, Nottingham, UK
PI US 6468782 20021022
SO Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 22, 2002) Vol. 1263, No. 4. http://www.uspto.gov/web/menu/patdata.html. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 4 Dec 2002
Last Updated on STN: 4 Dec 2002
AB This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.

L7 ANSWER 9 OF 24 USPATFULL on STN
AN 2002:236010 USPATFULL
TI DRIED BLOOD FACTOR COMPOSITION COMPRISING TREHALOSE
IN ROSER, BRUCE JOSEPH, CAMBRIDGESHIRE, UNITED KINGDOM
PI US 2002128207 A1 20020912
US 6649386 B2 20031118
AI US 1998-875796 A1 19981030 (8)
WO 1996-GB119 19960119
PRAI GB 1995-1040 19950119
DT Utility
FS APPLICATION
LREP DAVID R. SALIWANCHIK, 2421 N. W. 41ST STREET, SUIITE A-1, GAINESVILLE, FL, 32606-6669
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60 DEG C.

L7 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:868949 CAPLUS
DN 136:11285
TI Compositions for for stabilizing platelets for dry storage
IN Roser, Bruce J.; De Vos, Diana
PA UK
SO U.S. Pat. Appl. Publ., 15 pp., Cont. of U.S. Ser. No. 366,810, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001046487	A1	20011129	US 2001-894579	20010628
PRAI	US 1994-366810	B1	19941230		

AB The invention provides methods for drying platelets to obtain compns. which are storage stable over a wide range of temps. and for an extended period of time. The invention also provides methods for permeabilizing platelets which allows them to be loaded with various compds. Platelets were acid permeabilized. After addition of stop buffer, the mixture was centrifuged at room temperature at 1800 rpm for 10 min to pellet the platelets. Drying buffer was prepared by bringing the pH of HEPES-buffered saline to 7.0 using 2M and 0.2M NaOH. To 10 mL of this buffer 50 μL hirudin (10 U/mL); 6.25 μL apyrase (20 U/mL); 1 mg magnesium sulfate; 0.1 g trehalose; and 0.1 g. BSA were added. Resuspended platelets (300 μL) was carefully pipetted into 3 mL siliconized glass pharmaceutical vials and dried.

L7 ANSWER 11 OF 24 USPATFULL on STN
AN 2001:229650 USPATFULL
TI Dried blood factor composition comprising trehalose
IN Roser, Bruce Joseph, Cambridgeshire, Great Britain
PI US 2001051603 A1 20011213
AI US 2001-888734 A1 20010625 (9)
RLI Continuation of Ser. No. US 1998-875796, filed on 30 Oct 1998, PENDING
PRAI GB 1995-1040 19950119
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.

L7 ANSWER 12 OF 24 USPATFULL on STN
AN 2001:197000 USPATFULL
TI Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IN Colaco, Camilo, Cambridge, United Kingdom
Roser, Bruce J., Cambridge, United Kingdom
Sen, Shevanti, Cambridge, United Kingdom
PA Quardrant Holdings Cambridge, Ltd., United Kingdom (non-U.S. corporation)
PI US 6313102 B1 20011106
AI US 1999-389949 19990903 (9)
RLI Continuation of Ser. No. US 1994-293157, filed on 19 Aug 1994, now patented, Pat. No. US 5955448
PRAI GB 1994-73053 19940413
DT Utility
FS GRANTED

EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Maier, Leigh C.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses methods of increasing stability of biological substances during drying and the dried compositions derived therefrom. The compositions have improved storage stability.

L7 ANSWER 13 OF 24 USPATFULL on STN
AN 2001:59598 USPATFULL
TI Methods for producing dried storage-stable platelets and compositions obtained thereby
IN Roser, Bruce J., Cambridge, United Kingdom
Menys, Valentine, Cherry Hinton, United Kingdom
Grandage, Lynda, Haslingfield, United Kingdom
Phipps, Diana, Nassington, Netherlands
PA Quadrant Holdings Cambridge Ltd., Nottingham, United Kingdom (non-U.S. corporation)
PI US 6221575 B1 20010424
AI US 1998-19935 19980206 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Lankford, Jr., Leon B.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for drying platelets to obtain compositions which are storage stable over a wide range of temperatures and for an extended period of time. The invention also provides compositions obtained thereby and devices for use therein.

L7 ANSWER 14 OF 24 USPATFULL on STN
AN 2001:25468 USPATFULL
TI Composition and method for stable injectable liquids
IN Roser, Bruce Joseph, Cambridge, United Kingdom
Garcia De Castro, Arcadio, Cambridge, United Kingdom
Maki, James, Deerfield, IL, United States
PA Peter M. Ronai, Salem, OR, United States (U.S. corporation)
PI US 6190701 B1 20010220
AI US 1999-271204 19990317 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Jacobson, Price, Holman & Stern, PLLC
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 791
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for delivering a stable, bioactive compound to a subject comprising a first component and a second component, the first component comprises microparticles of sugar glass or a phosphate glass containing the bioactive agent. The sugar glass or phosphate glass optionally includes a glass formation facilitator compound, and the second component comprises at least one biocompatible liquid perfluorocarbon in which the first component is insoluble and dispersed. The liquid perfluorocarbon optionally includes a surfactant.

L7 ANSWER 15 OF 24 USPATFULL on STN
AN 1999:113734 USPATFULL
TI Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IN Colaco, Camilo, Cambridge, United Kingdom
Roser, Bruce J., Cambridge, United Kingdom
Sen, Shevanti, Cambridge, United Kingdom
PA Quadrant Holdings Cambridge Limited, Cambridge, United Kingdom (non-U.S. corporation)
PI US 5955448 19990921
AI US 1994-293157 19940819 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Eyler, Yvonne
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses methods of increasing stability of biological substances during drying and the dried compositions derived therefrom. The compositions have improved storage stability.

L7 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:548494 CAPLUS
DN 129:180123
TI Compositions for producing dried and storage-stable platelets
IN Menys, Valentine Charlton; Phipps, Diana Johanna; Grandage, Lynda Mary; Roser, Bruce Joseph
PA Quadrant Holdings Cambridge Limited, UK
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9834478	A1	19980813	WO 1998-GB375	19980206
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2279376	AA	19980813	CA 1998-2279376	19980206
	AU 9862208	A1	19980826	AU 1998-62208	19980206
	AU 732274	B2	20010412		
	EP 967862	A1	20000105	EP 1998-904260	19980206
	EP 967862	B1	20030115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6221575	B1	20010424	US 1998-19935	19980206
	JP 2001511174	T2	20010807	JP 1998-534003	19980206
	AT 230923	E	20030215	AT 1998-904260	19980206
	ES 2190063	T3	20030716	ES 1998-904260	19980206
	ZA 9801031	A	19980811	ZA 1998-1031	19980209
PRAI	US 1997-37493P	P	19970207		
	WO 1998-GB375	W	19980206		

AB The invention provides methods for drying platelets to obtain compns. which are storage stable over a wide range of temps. and for an extended period of time. The invention also provides compns. obtained and devices. Platelets were isolated from standard 1-30-day old platelet concs prepared from

blood collected from CPDA (16 mM sodium citrate, 29 mM D-glucose, 3.1 mM citric acid, 2.9 mM sodium phosphate, 0.36 adenine). After the addition of 0.8 μM PGI2 and 0.2 units/mL apyrase, the platelets were harvested by centrifugation. The supernatant was removed without disturbing the platelet pellet. The trehalose loading was assessed by using the radiolabeled sugar.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:774880 CAPLUS
TI Methods of preserving prokaryotic cells and compositions obtained thereby
IN Tunnacliffe, Alan G.; Welsh, David T.; Roser, Bruce Joseph; Dhaliwal, Kamaljit S.; Colaco, Camilo
PA Quadrant Holdings Cambridge Limited, UK
SO PCT Int. Appl., No pp. given
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824882	A1	19980611	WO 1997-GB3375	19971205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2272821	AA	19980611	CA 1997-2272821	19971205
	AU 9854034	A1	19980629	AU 1998-54034	19971205
	AU 721391	B2	20000629		
	ZA 9710974	A	19981228	ZA 1997-10974	19971205
	EP 946710	A1	19991006	EP 1997-947793	19971205
	EP 946710	B1	20051109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1239997	A	19991229	CN 1997-180328	19971205
	JP 2001505431	T2	20010424	JP 1998-525367	19971205
	AT 309326	E	20051115	AT 1997-947793	19971205
	US 2003113900	A1	20030619	US 2002-215060	20020807
PRAI	US 1996-32423P	P	19961205		
	US 1997-985343	A1	19971204		
	WO 1997-GB3375	W	19971205		

AB Unavailable

L7 ANSWER 18 OF 24 USPATFULL on STN
AN 97:31812 USPATFULL
TI Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
IN Roser, Bruce J., Balsham, England
Colaco, Camilo, Trumpington, England
PA Quadrant Holdings Cambridge Limited, Cambridge, England (non-U.S. corporation)
PI US 5621094 19970415
AI US 1994-255565 19940608 (8)
RLI Continuation of Ser. No. US 1992-965384, filed on 14 Dec 1992, now abandoned
PRAI GB 1990-10742 19900514
DT Utility
FS Granted

EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Saucier, S.
LREP Morrison & Foerster
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of preserving delicate biological substances or organic compounds (a) in a dry state and/or (b) at elevated temperatures and/or (c) under irradiation comprises incorporating in a system containing the said substances or compounds, a sugar or a sugar derivative selected from (i) a non-reducing glycoside of a polyhydroxy compound selected from sugar alcohols and other straight chain polyalcohols, or (ii) a non-reducing oligosaccharide selected from raffinose, stachyose and melezitose. In particular, methods for preserving dehydrated agarose gels comprising adding lactitol or glucopyranosyl-mannitol or glucopyranosyl-sorbitol to the gel during formation and prior to dehydration are disclosed.

L7 ANSWER 19 OF 24 USPATFULL on STN
AN 92:78842 USPATFULL
TI Preservation of viruses
IN Roser, Bruce J., Balsham, Great Britain
PA Quadrant Bioresources Limited, Cambridge, Great Britain (non-U.S. corporation)
PI US 5149653 19920922
WO 8906542 19890727
AI US 1989-411473 19891120 (7)
WO 1989-GB47 19890118
19891120 PCT 371 date
19891120 PCT 102(e) date
PRAI GB 1989-8801338 19890121
DT Utility
FS Granted
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Reardon, Timothy J.
LREP Gottlieb, Rackman & Reisman
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 258
AB A method of preserving live viruses comprises subjecting an aqueous system containing the virus to drying either in the frozen state or at ambient temperature, in the presence of trehalose.

L7 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:124367 CAPLUS
DN 116:124367
TI Stabilization of biological macromolecular substances and other organic compounds with nonreducing polyhydroxy glycosides or oligosaccharides
IN Roser, Bruce Joseph; Colaco, Camilo
PA Quadrant Holdings Cambridge Ltd., UK
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9118091	A1	19911128	WO 1991-GB759	19910514
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				

	AU 9178725	A1	19911210	AU 1991-78725	19910514
	EP 541556	A1	19930519	EP 1991-909487	19910514
	EP 541556	B1	19980916		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05508315	T2	19931125	JP 1991-509304	19910514
	JP 3101320	B2	20001023		
	AT 171209	E	19981015	AT 1991-909487	19910514
	ES 2125237	T3	19990301	ES 1991-909487	19910514
	US 5621094	A	19970415	US 1994-255565	19940608
PRAI	GB 1990-10742	A	19900514		
	WO 1991-GB759	A	19910514		
	US 1992-965384	B1	19921214		

AB (Bio)organic compds. are preserved in a dry state, at elevated temps., and/or under irradiation with nonreducing oligosaccharides or polyhydroxy glycosides. Restriction endonuclease PstI was dried at room temperature in the presence of trehalose then stored for 2 wks at 37°. The enzyme retained 100% of its original activity after this treatment.

L7 ANSWER 21 OF 24 USPATFULL on STN
AN 91:50338 USPATFULL
TI Dried food containing trehalose and method for preparing same
IN Roser, Bruce J., Cambridgeshire, Great Britain
PA Quadrant Bioresources, Limited, Cambridge, United Kingdom (non-U.S. corporation)
PI US 5026566 19910625
WO 8900012 19890112
AI US 1989-327187 19890501 (7)
WO 1988-GB511 19880629
19890501 PCT 371 date
19890501 PCT 102(e) date
DCD 20070102
PRAI GB 1987-15238 19870629
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne; Assistant Examiner: Pratt, Helen
LREP Coleman, Henry D., Sudol, R. Neil
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 304
AB A method of drying a water-containing foodstuff or beverage at a temperature above ambient, is characterized by incorporating trehalose into the foodstuff or beverage which is to be dried.

L7 ANSWER 22 OF 24 USPATFULL on STN
AN 90:1101 USPATFULL
TI Protection of proteins and the like
IN Roser, Bruce J., Balsham, Great Britain
PA Quadrant Bioresources Limited, Bedfordshire, England (non-U.S. corporation)
PI US 4891319 19900102
WO 8700196 19870115
AI US 1987-26695 19870507 (7)
WO 1986-GB396 19860709
19870507 PCT 371 date
19870507 PCT 102(e) date
PRAI GB 1985-17352 19850709
GB 1986-13066 19860529
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.
LREP Gottlieb, rackman & Reisman
CLMN Number of Claims: 12
ECL Exemplary Claim: 1,3,11

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sensitive proteins and other macromolecules, such as enzymes, antibodies, antigens, serum complement, fluorescent proteins, vaccine components, polysaccharides such as agarose etc, can be preserved by drying at ambient temperature and at atmospheric pressure in the presence of trehalose. A porous matrix impregnated with trehalose is provided as a receiver for a blood or other liquid sample to be dried.

L7 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:764111 CAPLUS
TI Preservation of viruses
IN Roser, Bruce Joseph
PA Quadrant Bioresources Limited, UK
SO PCT Int. Appl., No pp. given
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8906542	A1	19890727	WO 1989-GB47	19890118
	W: BR, GB, HU, JP, SU, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 357709	A1	19900314	EP 1989-901874	19890118
	EP 357709	B1	19930929		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02503266	T2	19901011	JP 1989-501732	19890118
	JP 06071423	B4	19940914		
	AT 95066	E	19931015	AT 1989-901874	19890118
	ES 2009704	A6	19891001	ES 1989-206	19890120
	CS 276472	B6	19920617	CS 1989-402	19890120
	CA 1333562	A1	19941220	CA 1989-588875	19890123
	US 5149653	A	19920922	US 1989-411473	19891120
PRAI	GB 1988-1338	A	19880121		
	EP 1989-901874	A	19890118		
	WO 1989-GB47	W	19890118		

AB Unavailable

L7 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:420354 CAPLUS
DN 107:20354
TI Protection of proteins and the like
IN Roser, Bruce Joseph
PA Quadrant Bioresources Ltd., UK
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8700196	A1	19870115	WO 1986-GB396	19860709
	W: AU, DK, GB, JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8661363	A1	19870130	AU 1986-61363	19860709
	AU 591160	B2	19891130		
	EP 229810	A1	19870729	EP 1986-904281	19860709
	EP 229810	B1	19911016		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 63500562	T2	19880303	JP 1986-503940	19860709
	JP 07079694	B4	19950830		

```
     AT 68524              E     19911115    AT 1986-904281          19860709
     GB 2187191            A1    19870903    GB 1987-4890            19870303
     GB 2187191            B2    19891101
     DK 8701207            A     19870309    DK 1987-1207            19870309
     DK 170173             B1    19950606
     CA 1307485            A1    19920915    CA 1987-531500          19870309
     US 4891319            A     19900102    US 1987-26695           19870507
     JP 11246593           A2    19990914    JP 1998-253492          19980908
PRAI GB 1985-17352         A     19850709
     GB 1986-13066         A     19860529
     EP 1986-904281        A     19860709
     JP 1986-503940        A3    19860709
     WO 1986-GB396         A     19860709
AB   Sensitive proteins and other macromols., such as enzymes, antibodies,
     antigens, serum complement, fluorescent proteins, vaccine components,
     polysaccharides such as agarose, etc., can be preserved by
     drying at ambient temperature and atmospheric pressure in the presence of
trehalose.  A
     porous matrix impregnated with trehalose is provided as a receiver for a
     blood or other liquid sample to be dried, e.g. prior to anal.  Alkaline
     phosphatase from calf intestine in phosphate-buffered saline was incubated
     in the wells of an immunoplate overnight.  The wells were washed and dried
     at 37° in the presence or absence of 5% trehalose in distilled water.
     The enzyme retained full activity on drying in the presence of trehalose,
     but lost >90% of its activity when dried in the absence of trehalose.


=> s preserv? and (stabiliz? agent?) and viscous
L8         1928 PRESERV? AND (STABILIZ? AGENT?) AND VISCOUS

=> s l8 and mbars
L9            1 L8 AND MBARS

=> d

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:387292  CAPLUS
DN   140:388255
TI   Drying process for biologicals and labile samples to be preserved
     as highly viscous liquids
IN   Mayeresse, Yves
PA   Glaxosmithkline Biologicals S.A., Belg.
SO   PCT Int. Appl., 42 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
PI   WO 2004039417          A2    20040513    WO 2003-EP12191         20031030
     WO 2004039417          A3    20041216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2503946             AA    20040513    CA 2003-2503946         20031030
     AU 2003287980          A1    20040525    AU 2003-287980          20031030
     EP 1556477             A2    20050727    EP 2003-779829          20031030
```

```
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003015733         A     20050906    BR 2003-15733          20031030
     CN 1732257            A     20060208    CN 2003-80107869       20031030
     JP 2006504801         T2    20060209    JP 2005-501819         20031030
     NO 2005001998         A     20050624    NO 2005-1998           20050425
     US 2006127415         A1    20060615    US 2006-533462         20060303
PRAI GB 2002-25520         A     20021101
     GB 2002-25532         A     20021101
     GB 2002-25543         A     20021101
     GB 2003-17371         A     20030724
     GB 2003-17380         A     20030724
     GB 2003-17381         A     20030724
     WO 2003-EP12191       W     20031030


=> s l8 and (cell or cells or bacter? or virus?)
L10       1458 L8 AND (CELL OR CELLS OR BACTER? OR VIRUS?)

=> dup rem l10
PROCESSING IS APPROXIMATELY  80% COMPLETE FOR L10
PROCESSING COMPLETED FOR L10
L11        1458 DUP REM L10 (0 DUPLICATES REMOVED)

=> s l11 and vaccine?
L12         98 L11 AND VACCINE?

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 98 ANSWERS - CONTINUE? Y/(N):y

L12  ANSWER 1 OF 98  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1194404  CAPLUS
DN   143:446917
TI   Drying process for biological and other labile samples using a polyol
     stabilizing agent
IN   Mayeresse, Yves
PA   Glaxosmithkline Biologicals S. A., Belg.
SO   PCT Int. Appl., 43 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2005105978        A2    20051110    WO 2005-EP4638         20050428
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
             SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
             ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI GB 2004-9795          A     20040430
AB   The present invention relates to a method of drying biol. and other labile
     samples so that they can be preserved as a highly
     viscous liquid  The method involves the steps of preparing a
     preservation sample by dissolving/suspending an active agent in a
     solution of a stabilizing agent, subjecting the
     preservation sample to such temperature and pressure conditions that the
```

preservation sample looses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid The stabilizing solution comprises a glass forming polyol and a second component which decreases the flow rate of the highly viscous liquid formed by the method. For example, inactivated poliovirus (IPV) was resuspended in an aqueous solution with 2.5% sucrose, 10% sucrose or 10% trehalose as the stabilizing agent and dried at 15° and pressure of 35 mbar. As water evaporated from the sample, the temperature dropped to 4° but towards the end of the 2 h, the temperature returned to 15° as the rate of evaporation slowed. No bubbling or foam formation occurred under these conditions. The pressure was then reduced further to 0.1 mbar and these conditions were maintained for 16 h more in the first two expts. and for 10 h more in the third experiment The samples were reconstituted in water and an ELISA was used to assess the degree of antigen retention. The levels of type 3 IPV antigen retention compares very favorably with the freeze drying results.

L12 ANSWER 2 OF 98 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:387292 CAPLUS
DN 140:388255
TI Drying process for biologicals and labile samples to be preserved as highly viscous liquids
IN Mayeresse, Yves
PA Glaxosmithkline Biologicals S.A., Belg.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039417	A2	20040513	WO 2003-EP12191	20031030
	WO 2004039417	A3	20041216		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503946	AA	20040513	CA 2003-2503946	20031030
	AU 2003287980	A1	20040525	AU 2003-287980	20031030
	EP 1556477	A2	20050727	EP 2003-779829	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015733	A	20050906	BR 2003-15733	20031030
	CN 1732257	A	20060208	CN 2003-80107869	20031030
	JP 2006504801	T2	20060209	JP 2005-501819	20031030
	NO 2005001998	A	20050624	NO 2005-1998	20050425
	US 2006127415	A1	20060615	US 2006-533462	20060303
PRAI	GB 2002-25520	A	20021101		
	GB 2002-25532	A	20021101		
	GB 2002-25543	A	20021101		
	GB 2003-17371	A	20030724		
	GB 2003-17380	A	20030724		
	GB 2003-17381	A	20030724		
	WO 2003-EP12191	W	20031030		

AB The present invention relates to a method of drying biol. and other labile samples so that they can be preserved as a highly viscous liquid The method involves the steps of preparing a

preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample loses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid IPV (inactivated polio virus) was resuspended in an aqueous solution with 10 % sucrose or 10 % trehalose as the stabilizing agent. The samples were put into siliconized vials which were placed into a Heto Drywinner 8-85 freeze-dryer and the temperature was set to 15°. The pressure was initially reduced to 35 mBars to degas the sample. After 10 min, the pressure was further reduced to 8 mBars and was kept at this level for two hours. As water evaporated from the sample, the temperature dropped to 4° but towards the end of the two hours, the temperature returned to 15° as the rate of evaporation slowed. No bubbling or foam formation occurred under these conditions. The pressure was then reduced further to 0.1 mBars and these conditions were maintained for 16 h more in the first two expts. and for 10 h more in the third experiment IPV which had been dried by this method could be stored at 4° for at least 9 mo without loss of antigenicity.

L12 ANSWER 3 OF 98 USPATFULL on STN
AN 2006:214618 USPATFULL
TI Formulations for ocular treatment
IN Dor, Philippe JM, Cupertino, CA, UNITED STATES
Mudumba, Sreenivasu, Union City, CA, UNITED STATES
Nivaggioli, Thierry, Atherton, CA, UNITED STATES
Weber, David A., Danville, CA, UNITED STATES
PI US 2006182771 A1 20060817
AI US 2006-351844 A1 20060209 (11)
PRAI US 2005-664306P 20050321 (60)
US 2005-664040P 20050321 (60)
US 2005-651790P 20050209 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3358
AB Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.

L12 ANSWER 4 OF 98 USPATFULL on STN
AN 2006:158696 USPATFULL
TI Compositions useful to treat ocular neovascular diseases and macular degeneration
IN Leonard, Todd, Minnetonka, MN, UNITED STATES
PI US 2006134226 A1 20060622
AI US 2005-280960 A1 20051116 (11)
PRAI US 2004-628162P 20041116 (60)
DT Utility
FS APPLICATION

LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a composition that includes: (a) xanthophylls; (b) vitamin C; (c) vitamin E; (d) zinc; and (e) copper. The present invention also provides a method of treating macular degeneration in a human, inhibiting angiogenesis in a human, preventing impairment of the vision or for improving impaired vision of a human whose eye has drusen, and/or treating a disease associated with ocular neovascularitis in a human. The methods include administering to a human in need of such treatment an effective amount of the composition of the present invention.

L12 ANSWER 5 OF 98 USPATFULL on STN
AN 2006:158675 USPATFULL
TI Process for preparing a pharmaceutical composition
IN Busson, Patrick, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Schroeder, Marco, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2006134205 A1 20060622
AI US 2006-354716 A1 20060215 (11)
RLI Division of Ser. No. US 2002-266363, filed on 8 Oct 2002, PENDING
Continuation of Ser. No. US 2001-891069, filed on 25 Jun 2001, GRANTED, Pat. No. US 6534087
PRAI EP 2000-113535 20000627
DT Utility
FS APPLICATION
LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110, US
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

L12 ANSWER 6 OF 98 USPATFULL on STN
AN 2006:152213 USPATFULL
TI Pharmaceutical formulation of cytidine analogs and derivatives
IN Tang, Chunlin, Walnut Creek, CA, UNITED STATES
Joshi-Hangal, Rajashree, Pleasanton, CA, UNITED STATES
PI US 2006128654 A1 20060615
AI US 2004-10189 A1 20041210 (11)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides pharmaceutical formulations of cytidine

analogs and derivatives, such as 5-azacytidine, 5-aza-2'-deoxy-2',2'-difluorocytidine, 5-aza-2'-deoxy-2'-fluorocytidine, 2'-deoxy-2',2'-difluorocytidine, and cytosine 1-β-D-arabinofuranoside, as well as methods of manufacturing the formulations. In particular, the cytidine analog or derivative is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering the cytidine analog or derivative to treat conditions or diseases, such as cancer and hematological disorders.

L12 ANSWER 7 OF 98 USPATFULL on STN
AN 2006:152212 USPATFULL
TI Pharmaceutical formulation of decitabine
IN Tang, Chunlin, Walnut Creek, CA, UNITED STATES
Joshi-Hangal, Rajashree, Pleasanton, CA, UNITED STATES
PI US 2006128653 A1 20060615
AI US 2004-9540 A1 20041210 (11)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides pharmaceutical formulations of decitabine or 5-aza-2'-deoxycytidine as well as methods of manufacturing the formulations. In particular, decitabine is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering decitabine to treat conditions or diseases, such as cancer and hematological disorders.

L12 ANSWER 8 OF 98 USPATFULL on STN
AN 2006:143607 USPATFULL
TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
IN Jin, Tuo, Tianjin, CHINA
Zhu, Hua, Plainboro, NJ, UNITED STATES
Zhu, Jiahao, Brooklyn, NY, UNITED STATES
PI US 2006121121 A1 20060608
AI US 2003-517122 A1 20030603 (10)
WO 2003-CN431 20030603
20060126 PCT 371 date
PRAI US 2002-60384971 20020603
US 2002-10291327 20021108
US 2002-418100P 20021011 (60)
DT Utility
FS APPLICATION
LREP Albert Wai-Kit Chan, Law Offices of Albert Wai-Kit Chan, World Plaza, Suite 604,, 141-07 20th Avenue, Whitestone, NY, 11357, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using unique emulsion system (Stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysacchride glassy particles under a condition free of any chemical or physical hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and cross-linking agents.

Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the technical challenges raised in sustained release delivery of proteins.

L12 ANSWER 9 OF 98 USPATFULL on STN
AN 2006:131782 USPATFULL
TI Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Attar, Ricardo M., Lawrenceville, NJ, UNITED STATES
Gottardis, Marco M., Princeton, NJ, UNITED STATES
Balog, James Aaron, Scotch Plains, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Martinez, Rogelio L., Monmouth Junction, NJ, UNITED STATES
Sun, Chongqing, East Windsor, NJ, UNITED STATES
PI US 2006111424 A1 20060525
AI US 2005-311731 A1 20051219 (11)
RLI Continuation of Ser. No. US 2002-75870, filed on 14 Feb 2002, PENDING
PRAI US 2001-271672P 20010227 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 10 OF 98 USPATFULL on STN
AN 2006:118441 USPATFULL
TI Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
IN Bague, Severine, Marcoussis, FRANCE
Philips, Betty, Antony, FRANCE
Garrigue, Jean-Sebastien, Verrieres Le Buisson, FRANCE
Rabinovich-Guilatt, Laura, Paris, FRANCE
Lambert, Gregory, Chatenay, FRANCE
PA NOVAGALI PHARMA SA (non-U.S. corporation)
PI US 2006100288 A1 20060511
AI US 2004-991346 A1 20041118 (10)
PRAI EP 2004-292645 20041109
DT Utility
FS APPLICATION
LREP STEPTOE & JOHNSON LLP, 1330 CONNECTICUT AVENUE, N.W., WASHINGTON, DC, 20036, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.

L12 ANSWER 11 OF 98 USPATFULL on STN
AN 2006:111138 USPATFULL
TI Composition of lactoferrin related peptides and uses thereof
IN Varadhachary, Atul, Houston, TX, UNITED STATES
Glynn, Peter, Houston, TX, UNITED STATES
Petrak, Karel, Houston, TX, UNITED STATES
Engelmayer, Jose, Houston, TX, UNITED STATES
PA AGENNIX INCORPORATED, Houston, TX, UNITED STATES (U.S. corporation)
PI US 2006094082 A1 20060504
AI US 2005-258767 A1 20051026 (11)
PRAI US 2004-622176P 20041026 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 8741
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

L12 ANSWER 12 OF 98 USPATFULL on STN
AN 2006:105189 USPATFULL
TI Sperm specific lysozyme-like proteins
IN Herr, John C., Charlottesville, VA, UNITED STATES
Herrero, Maria Belen, Alexandria, VA, UNITED STATES
Mandal, Arabinda, Charlottesville, VA, UNITED STATES
Digilio, Laura Clayton, Crozet, VA, UNITED STATES
PI US 2006089297 A1 20060427
AI US 2004-542038 A1 20040116 (10)
WO 2004-US1240 20040116
20050713 PCT 371 date
PRAI US 2003-440585P 20030116 (60)
DT Utility
FS APPLICATION
LREP UNIVERSITY OF VIRGINIA PATENT FOUNDATION, 250 WEST MAIN STREET, SUITE 300, CHARLOTTESVILLE, VA, 22902, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a family of testis specific proteins (SLLPs) that share high sequence identity to lysozyme-C proteins. The application encompasses compositions comprising the SLLP proteins, antibodies specific for the SLLP polypeptides and the use of the SLLP polypeptides and antibodies directed to such peptides as contraceptive agents.

L12 ANSWER 13 OF 98 USPATFULL on STN
AN 2006:79892 USPATFULL
TI Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof
IN Krom, James A., Belmont, MA, UNITED STATES
Schwarz, Alexander, Brookline, MA, UNITED STATES
PA Biosphere Medical, Inc., Rockland, MA, UNITED STATES (U.S. corporation)
PI US 2006067883 A1 20060330
AI US 2005-185449 A1 20050719 (11)
PRAI US 2004-613098P 20040924 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT

BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB One aspect of the present invention relates to a microsphere, comprising a hydrophilic polymer comprising a plurality of pendant anionic groups; a transition-metal, lanthanide or group 13-14 metal oxide, polyoxometalate or metal hydroxide or combination thereof; and a first radioisotope that emits a therapeutic β-particle. In certain embodiments, the microsphere further comprsies a second radioisotope that emits a diagnostic γ-ray; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, the microsphere is composed of polymer impregnated with zirconia bound to .sup.32p as the source of the therapeutic β-emissions and .sup.67Ga as the source of the diagnostic γ-emissions. Another aspect of the present invention relates to the preparation of a microsphere impregnated with a radioisotope that emits therapeutic β-particles and a radioisotope that emits diagnostic β-emitting radioisotope and a γ-emitting radioistope; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, said microspheres are administered to the patient through a catheter. In another embodiment, the microsphere is combined with the radioisotopes at the site of treatment.

L12 ANSWER 14 OF 98 USPATFULL on STN
AN 2006:66914 USPATFULL
TI Malleable protein matrix and uses thereof
IN Simard, Eric, Laval, CANADA
Pilote, Dominique, Chicoutimi, CANADA
DuPont, Claude, Blainville, CANADA
Lajoie, Nathalie, Jonquiere, CANADA
Paquet, Marcel, Chicoutimi, CANADA
Lemieux, Pierre, Ste-Therese, CANADA
Goyette, Philippe, Montreal, CANADA
PI US 2006057131 A1 20060316
AI US 2002-499313 A1 20021220 (10)
WO 2002-CA1988 20021220
20050224 PCT 371 date
PRAI US 2001-60341232 20011220
DT Utility
FS APPLICATION
LREP CALFEE HALTER & GRISWOLD, LLP, 800 SUPERIOR AVENUE, SUITE 1400, CLEVELAND, OH, 44114, US
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a malleable protein matrice (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the process for the preparation of the malleable protein matrice and its usages.

L12 ANSWER 15 OF 98 USPATFULL on STN
AN 2006:41161 USPATFULL
TI Methods and formulations comprising agonists and antagonists of nuclear hormone receptors
IN Sternberg, Esther M., 3610 UPTON AVENUE N.W., WASHINGTON, DC, UNITED

STATES 20008
Webster, Jeannette I., Washington, DC, UNITED STATES
Tonelli, Leonardo H., Bethesda, MD, UNITED STATES
Leppla, Stephen H., Bethesda, MD, UNITED STATES
Moayeri, Mahtab, Bethesda, MD, UNITED STATES
PI US 2006035813 A1 20060216
AI US 2003-530254 A1 20031003 (10)
WO 2003-US31406 20031003
20050404 PCT 371 date
PRAI US 2002-416222P 20021004 (60)
US 2003-419454P 20021018 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds, pharmaceutical compositions, and methods are provided for modulating processes mediated by nuclear hormone receptors. A partial or complete agonist or antagonist modulates, directly or indirectly, an activity of one or more nuclear hormone receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), vitamin D (VDRs), retinoids (RARs and RXRs), peroxisomes (XPARs and PPARs), icosanoids (IRs), or one or more orphan receptors, such as steroid and thyroid receptors. Exemplary compounds of the disclosure are bacterial products, for example bacterial toxins, and these compounds are useful in screens for other antagonists and agonists. Related methods and compositions are provided for diagnosis, treatment and prevention of bacterial disease and associated or unrelated inflammatory, autoimmune, toxic (including shock), and chronic and/or lethal sequelae associated with bacterial infection.

L12 ANSWER 16 OF 98 USPATFULL on STN
AN 2006:40244 USPATFULL
TI Biodegradable controlled release bioactive agent delivery device
IN Lawin, Laurie, New Brighton, MN, UNITED STATES
Anderson, Aron B., Minnetonka, MN, UNITED STATES
PI US 2006034891 A1 20060216
AI US 2005-175910 A1 20050705 (11)
PRAI US 2004-600930P 20040812 (60)
DT Utility
FS APPLICATION
LREP KARRIE WEAVER, Kagan Binder, PLLC, Suite 200, 221 Main Street North, Stillwater, MN, 55082, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides implantable medical devices that are fabricated, at least in part, from biodegradable polymeric material. The implantable medical devices are used to provide bioactive agent to a treatment site, and are particularly useful for treatment of limited access regions of the body.

L12 ANSWER 17 OF 98 USPATFULL on STN
AN 2006:27949 USPATFULL
TI WWOX: A TUMOR SUPPRESSOR GENE MUTATED IN MULTIPLE CANCERS
IN Aldaz, Marcelo C., Austin, TX, UNITED STATES

Bednarek, Andrzej, Smithville, TX, UNITED STATES
PI US 2006024780 A1 20060202
US 7060811 B2 20060613
AI US 2001-978318 A1 20011015 (9)
PRAI US 2000-240277P 20001013 (60)
DT Utility
FS APPLICATION
LREP Gina N. Shishima, FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS AVENUE, AUSTIN, TX, 78701, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1-73
DRWN 5 Drawing Page(s)
LN.CNT 6447
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides the isolation and cloning of WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in several cancers. This gene encodes a tumor suppressor with apoptotic functions. The invention provides WWOX nucleic acid- and polypeptide-based cancer therapies. The invention also provides methods for cancer detection, diagnosis and prognosis involving WWOX nucleic acids and polypeptides.

L12 ANSWER 18 OF 98 USPATFULL on STN
AN 2006:21007 USPATFULL
TI Methods and compositions using cholinesterase inhibitors
IN Ieni, John, Bloomfield, NJ, UNITED STATES
Pratt, Raymond, Baltimore, MD, UNITED STATES
PA Eisai Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 2006018839 A1 20060126
AI US 2004-988600 A1 20041116 (10)
RLI Continuation of Ser. No. WO 2003-US15279, filed on 16 May 2003, PENDING
PRAI US 2003-447724P 20030219 (60)
US 2002-380852P 20020517 (60)
DT Utility
FS APPLICATION
LREP VENABLE LLP, P.O. BOX 34385, WASHINGTON, DC, 20045-9998, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.

L12 ANSWER 19 OF 98 USPATFULL on STN
AN 2006:15457 USPATFULL
TI Controlled release bioactive agent delivery device

IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
de Juan, Eugene, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2006013835 A1 20060119
AI US 2005-225301 A1 20050912 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a controlled release bioactive agent delivery device for treatment of an eye that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The first polymer and the second polymer are hydrophobic, and the body member has a length such that, upon placement of the device at an implantation site within a posterior segment of an eye, the device does not enter a central visual field of the eye. The invention also provides methods method of delivering bioactive agent to a posterior region of an eye.

L12 ANSWER 20 OF 98 USPATFULL on STN
AN 2006:3508 USPATFULL
TI Use of emulsions for intra and periocular injections
IN Rabinovich-Guilatt, Laura, Paris, FRANCE
De Kozak, Yvonne, Paris, FRANCE
Dubernet, Catherine, Epinay/Sur/Orge, FRANCE
Lambert, Gregory, Verrieres Le Buisson, FRANCE
Benita, Simon, Mevasseret Sion, ISRAEL
Couvreur, Patrick, Bures sur Yvette, FRANCE
Behar-Cohen, Francine, Paris, FRANCE
PI US 2006002963 A1 20060105
AI US 2004-891452 A1 20040715 (10)
PRAI EP 2004-291684 20040702
DT Utility
FS APPLICATION
LREP STEPTOE & JOHNSON LLP, ATTORNEYS AT LAW, 1330 Connecticut Avenue, NW, Washington, DC, 20036-1795, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating eye diseases by injecting intraocularly or periocularly a composition comprising an emulsion and optionally at least a pharmaceutical active ingredient.

L12 ANSWER 21 OF 98 USPATFULL on STN
AN 2005:330212 USPATFULL
TI Controlled release bioactive agent delivery device
IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES

Shen, Byron C., Eden Prairie, MN, UNITED STATES
de Juan, Eugene, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2005287188 A1 20051229
AI US 2005-203981 A1 20050815 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides retrievable devices for sustained delivery of bioactive agent to a site within a patient, the devices including a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension; a cap at the proximal end of the body member; and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent.

L12 ANSWER 22 OF 98 USPATFULL on STN
AN 2005:323957 USPATFULL
TI Controlled release bioactive agent delivery device
IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
de Juan, Eugene, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2005281863 A1 20051222
AI US 2005-203931 A1 20050815 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides controlled release bioactive agent delivery devices that include a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent, wherein the first polymer and the second polymer are hydrophobic. The invention also provides methods of delivering a bioactive agent to a patient in a controlled release manner, as well as methods of making controlled release bioactive agent delivery devices.

L12 ANSWER 23 OF 98 USPATFULL on STN
AN 2005:318098 USPATFULL
TI Controlled release bioactive agent delivery device

IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
de Juan, Eugene, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2005276837 A1 20051215
AI US 2005-204195 A1 20050815 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a controlled release bioactive agent delivery device that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The invention also provides methods of delivering a bioactive agent to a patient in a controlled release manner, as well as methods of making a controlled release bioactive agent delivery device.

L12 ANSWER 24 OF 98 USPATFULL on STN
AN 2005:313180 USPATFULL
TI Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Fura, Aberra, Lawrenceville, NJ, UNITED STATES
Li, Wenying, Middletown, CT, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
Mitt, Toomas, Plainsboro, NJ, UNITED STATES
Roberge, Jacques Y., Princeton, NJ, UNITED STATES
Corte, James R., Lawrenceville, NJ, UNITED STATES
Spergel, Steven H., Warrington, PA, UNITED STATES
Rampulla, Richard A., Flemington, NJ, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Xiao, Hai-Yun, Princeton, NJ, UNITED STATES
PI US 2005272799 A1 20051208
AI US 2005-176810 A1 20050707 (11)
RLI Continuation of Ser. No. US 2004-974049, filed on 25 Oct 2004, PENDING
Continuation of Ser. No. US 2002-322077, filed on 18 Dec 2002, ABANDONED
Continuation-in-part of Ser. No. US 2001-25116, filed on 19 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885381, filed on 20 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885827, filed on 20 Jun 2001, PENDING
PRAI US 2001-284730P 20010418 (60)
US 2001-284438P 20010418 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 8

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 17461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 25 OF 98 USPATFULL on STN
AN 2005:312089 USPATFULL
TI Controlled release bioactive agent delivery device
IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
Juan, Eugene de, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2005271706 A1 20051208
AI US 2005-204271 A1 20050815 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for delivering bioactive agent to an eye, the methods including steps of providing a device at an implantation site within the eye, and maintaining the device at the implantation site to provide a therapeutically effective amount of the bioactive agent to the eye. The device includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension. A polymeric coated composition is provided in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The invention also provides methods of administering a therapeutically effective amount of bioactive agent to a posterior segment of an eye.

L12 ANSWER 26 OF 98 USPATFULL on STN
AN 2005:312086 USPATFULL
TI Controlled release bioactive agent delivery device
IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
de Juan, Eugene, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
Chappa, Ralph A., Prior Lake, MN, UNITED STATES
PI US 2005271703 A1 20051208
AI US 2005-203879 A1 20050815 (11)
RLI Continuation of Ser. No. US 2004-835530, filed on 29 Apr 2004, PENDING
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 44
ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)
LN.CNT 2415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides implantable sustained release bioactive agent delivery devices that include a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension; and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The polymeric coated composition is formulated to provide controlled release of bioactive agent over time when introduced into physiological conditions. Methods of preparing implantable devices configured and formulated to provide controlled release of bioactive agent are also provided.

L12 ANSWER 27 OF 98 USPATFULL on STN
AN 2005:311981 USPATFULL
TI Body cavity foams
IN Friedman, Doron, Karmei Yosef, ISRAEL
Besonov, Alex, Rehovet, ISRAEL
Tamarkin, Dov, Maccabim, ISRAEL
Eini, Meir, Ness Ziona, ISRAEL
PA Foamix Ltd. (non-U.S. corporation)
PI US 2005271598 A1 20051208
AI US 2005-116761 A1 20050428 (11)
RLI Continuation-in-part of Ser. No. US 532618, PENDING A 371 of International Ser. No. WO 2003-IB5527, filed on 24 Oct 2003
PRAI IL 2002-152486 20021025
US 2002-429546P 20021129 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.

L12 ANSWER 28 OF 98 USPATFULL on STN
AN 2005:298523 USPATFULL
TI Therapeutic and cosmetic uses of heparanases
IN Ilan, Neta, Rehovot, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Yacoby-Zeevi, Oron, Moshav Bizaron, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PA Insight Strategy & Marketing Ltd. (non-U.S. corporation)
Hadasit Medical Research Services and Development Ltd. (non-U.S. corporation)
PI US 2005260187 A1 20051124
AI US 2005-106672 A1 20050415 (11)
RLI Continuation of Ser. No. US 2003-341582, filed on 14 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001, GRANTED, Pat. No. US 6790658 Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001, PENDING Continuation of Ser. No. US 1999-258892,

filed on 1 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31 Aug 1998, PENDING Continuation-in-part of Ser. No. WO 2001-IL830, filed on 5 Sep 2001, UNKNOWN Continuation-in-part of Ser. No. US 2000-727479, filed on 4 Dec 2000, ABANDONED
PRAI US 2000-231551P 20000911 (60)
US 2000-244593P 20001101 (60)
DT Utility
FS APPLICATION
LREP Martin MOYNIHAN, c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 49 Drawing Page(s)
LN.CNT 7085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.

L12 ANSWER 29 OF 98 USPATFULL on STN
AN 2005:288981 USPATFULL
TI Method for stably incorporating substances within dry, foamed glass matrices
IN Roser, Bruce, Cambridge, UNITED KINGDOM
Gribbon, Enda Martin, Cambridge, UNITED KINGDOM
PA Elan Drug Delivery Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)
PI US 6964771 B1 20051115
AI US 1997-923783 19970904 (8)
RLI Continuation of Ser. No. US 1995-486043, filed on 7 Jun 1995, PENDING
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saucier, Sandra E.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

L12 ANSWER 30 OF 98 USPATFULL on STN
AN 2005:287487 USPATFULL
TI Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
IN Fink, Brian E., West Windsor, NJ, UNITED STATES
Gavai, Ashvinikumar V., Princeton Junction, NJ, UNITED STATES
Vite, Gregory D., Titusville, NJ, UNITED STATES
Han, Wen-Ching, Newtown, PA, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Xiao, Hai-Yun, Belle Mead, NJ, UNITED STATES
Norris, Derek J., Pennington, NJ, UNITED STATES
Tokarski, John S., Princeton, NJ, UNITED STATES
PI US 2005250753 A1 20051110
AI US 2005-66373 A1 20050225 (11)
PRAI US 2004-548851P 20040301 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 28

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

L12 ANSWER 31 OF 98 USPATFULL on STN
AN 2005:280559 USPATFULL
TI Composition for enhancing absorption of a drug and method
IN Mathias, Neil R., North Brunswick, NJ, UNITED STATES
Li, Lianli, Pomona, NY, UNITED STATES
PI US 2005244502 A1 20051103
AI US 2005-113839 A1 20050425 (11)
PRAI US 2004-566049P 20040428 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for enhancing absorption of a pharmaceutical which may have poor oral bioavailability, which composition has surprisingly little cytotoxicity, is provided which is in the form of a liquid or semi-solid or solid containing an admixture (1) a mucoadhesive polymer which is a polyacrylic acid polymer, preferably Carbopol 971P, and (2) an absorption or permeation enhancer which preferably is L-α-lyso-phosphatidylcholine (LPC), and which composition is free of polysaccharides. A method for improving bioavailability of a drug which has poor absorption properties is also provided wherein the above bioadhesive composition is administered with said pharmaceutical to the mucosal membrane of the GI tract, nose, oral cavity, sublingual, buccal, and vaginal mucosa. A method for reducing the cytotoxic effect of an absorption enhancer such as LPC is also provided wherein a mucoadhesive polymer as described above is administered with the LPC to a patient in need of treatment.

L12 ANSWER 32 OF 98 USPATFULL on STN
AN 2005:280423 USPATFULL
TI Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers
IN Labib, Mohamed E., Princeton, NJ, UNITED STATES
Rando, Robert F., Annandale, NJ, UNITED STATES
PA Novaflux Biosciences, Inc., Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 2005244365 A1 20051103
AI US 2004-837153 A1 20040503 (10)
DT Utility
FS APPLICATION
LREP Rando, Robert F., c/o Novaflux Biosciences Inc., 1 Wall Street, Princeton, NJ, 08540, US
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2

(HSV2), or other virus), or a bacterial infection (such as Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl, or Chlamydia trachomatis, or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.

L12 ANSWER 33 OF 98 USPATFULL on STN
AN 2005:265557 USPATFULL
TI Fast-dissolving films
IN Bess, William S., Edison, NJ, UNITED STATES
PI US 2005230871 A1 20051020
AI US 2005-110412 A1 20050420 (11)
PRAI US 2004-563610P 20040420 (60)
DT Utility
FS APPLICATION
LREP PFIZER, INC., 201 TABOR ROAD, MORRIS PLAINS, NJ, 07950, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 233
AB The present invention relates to consumable film products and a method for producing same. More particularly, one aspect of the invention provides a method of making a consumable film by forming a composition into a ribbon, feeding the ribbon to one or more dies, cutting the ribbon into sections, and drying the sections. One or more ribbons may be simultaneously treated. The dies of the invention may be configured to produce an array of variously shaped products having a thickness of less than about 1/8". Another aspect of the invention provides single-layer films and multiple-layer films produced according to the disclosed methods.

L12 ANSWER 34 OF 98 USPATFULL on STN
AN 2005:254360 USPATFULL
TI Apparatus and method for transdermal delivery of influenza vaccine
IN Maa, Yuh-Fun, Millbrae, CA, UNITED STATES

Sellers, Scott, San Mateo, CA, UNITED STATES
Matriano, James, Mountain View, CA, UNITED STATES
Ramdas, Asha, Sunnyvale, CA, UNITED STATES
PI US 2005220854 A1 20051006
AI US 2005-84631 A1 20050318 (11)
PRAI US 2004-559153P 20040401 (60)
DT Utility
FS APPLICATION
LREP Ralph C. Francis, Francis Law Group, 1942 Embarcadero, Oakland, CA, 94606, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 2037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An apparatus and method for transdermally delivering an immunologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers, the microprojection member having a biocompatible coating disposed thereon that includes the immunologically active agent. Preferably, the biocompatible coating is formed from a vaccine coating formulation.

L12 ANSWER 35 OF 98 USPATFULL on STN
AN 2005:248435 USPATFULL
TI Diarylheptanoid compounds and uses thereof
IN Rafi, M. Mohamed, Highland Park, NJ, UNITED STATES
Liu, Zhihua, Howell, NJ, UNITED STATES
Rosen, Robert T., Monroe Township, NJ, UNITED STATES
Rosen, Sharon L., UNITED STATES legal representative
Ho, Chi-Tang, East Brunswick, NJ, UNITED STATES
PI US 2005215635 A1 20050929
AI US 2005-75275 A1 20050308 (11)
PRAI US 2004-551182P 20040308 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to diarylheptanoid compounds and compositions comprising a diarylheptanoid compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more diarylheptanoid compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more diarylheptanoid compounds. The present invention further relates to articles of manufacture comprising one or more diarylheptanoid compounds.

L12 ANSWER 36 OF 98 USPATFULL on STN
AN 2005:237096 USPATFULL
TI Retinoid immunomodulating kit and composition and uses thereof
IN Tamarkin, Dov, Maccabim, ISRAEL
Eini, Meir, Ness Ziona, ISRAEL
Friedman, Doron, Karmei Yosef, ISRAEL
PA Foamix Ltd. (non-U.S. corporation)
PI US 2005205086 A1 20050922
AI US 2005-78948 A1 20050311 (11)

RLI Continuation-in-part of Ser. No. US 2004-911367, filed on 4 Aug 2004, PENDING Continuation-in-part of Ser. No. WO 2003-IB5527, filed on 24 Oct 2003, UNKNOWN
PRAI IL 2002-152486 20021025
US 2003-492385P 20030804 (60)
US 2002-429546P 20021129 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a retinoid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a retinoid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof.

L12 ANSWER 37 OF 98 USPATFULL on STN
AN 2005:226574 USPATFULL
TI Novel tissue engineered scaffolds derived from copper capillary alginate gels
IN Batich, Christopher D., Gainesville, FL, UNITED STATES
Willenberg, Bradley Jay, Gainesville, FL, UNITED STATES
Hamazaki, Takashi, Gainesville, FL, UNITED STATES
Terada, Naohiro, Gainesville, FL, UNITED STATES
PI US 2005196423 A1 20050908
AI US 2005-74285 A1 20050307 (11)
PRAI US 2004-550910P 20040305 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 1818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides copper capillary alginate gels stabilized with barium, chitosan, its derivates, or a combination thereof. These stabilized gels are useful as scaffolds for containing, growing, or regenerating biological agents and cells for in vivo or in vitro use.

L12 ANSWER 38 OF 98 USPATFULL on STN
AN 2005:221516 USPATFULL
TI Fused heterocyclic succinimide compounds and analogs thereof, modulators

of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Fura, Aberra, Lawrenceville, NJ, UNITED STATES
Li, Wenying, Middletown, CT, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
Mitt, Toomas, Plainsboro, NJ, UNITED STATES
Roberge, Jacques Y., Princeton, NJ, UNITED STATES
Corte, James R., Lawrenceville, NJ, UNITED STATES
Spergel, Steven H., Warrington, PA, UNITED STATES
Rampulla, Richard A., Flemington, NJ, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Xiao, Hai-Yun, Princeton, NJ, UNITED STATES
PI US 2005192253 A1 20050901
AI US 2004-974049 A1 20041025 (10)
RLI Continuation of Ser. No. US 2002-322077, filed on 18 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2001-25116, filed on 19 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885381, filed on 20 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-885827, filed on 20 Jun 2001, PENDING
PRAI US 2001-284730P 20010418 (60)
US 2001-284438P 20010418 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1-26
DRWN No Drawings
LN.CNT 17914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 39 OF 98 USPATFULL on STN
AN 2005:214582 USPATFULL
TI Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
IN Roser, Bruce, Cambridge, UNITED KINGDOM
Gribbon, Enda Martin, Cambridge, UNITED KINGDOM
PA Elan Drug Delivery Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)
PI US 2005186254 A1 20050825
AI US 2005-81356 A1 20050315 (11)
RLI Continuation of Ser. No. US 1997-923783, filed on 4 Sep 1997, PENDING Continuation of Ser. No. US 1995-486043, filed on 7 Jun 1995, ABANDONED
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-77
DRWN 6 Drawing Page(s)
LN.CNT 923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

L12 ANSWER 40 OF 98 USPATFULL on STN
AN 2005:138578 USPATFULL
TI METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Mitt, Toomas, Plainsboro, NJ, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
Brzozowski, David, Piscataway, NJ, UNITED STATES
Goswami, Animesh, Plainsboro, NJ, UNITED STATES
Chu, Linda Nga Hoong, East Brunswick, NJ, UNITED STATES
Li, Wen-sen, Holmdel, NJ, UNITED STATES
Simpson, James H., Hillsborough, NJ, UNITED STATES
Totleben, Michael J., North Brunswick, NJ, UNITED STATES
He, Weixuan, Dayton, NJ, UNITED STATES
PI US 2005119228 A1 20050602
US 6953679 B2 20051011
AI US 2001-24878 A1 20011219 (10)
RLI Continuation-in-part of Ser. No. US 2001-885381, filed on 20 Jun 2001, PENDING
PRAI US 2000-233519P 20000919 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 41 OF 98 USPATFULL on STN
AN 2005:123768 USPATFULL
TI Immunogenic formulations comprising oil bodies
IN Deckers, Harm M., Calgary, CANADA
Rooijen, Gijs Van, Calgary, CANADA
Boothe, Joseph, Calgary, CANADA
Goll, Janis, Calgary, CANADA
Moloney, Maurice M., Calgary, CANADA
Schryvers, Anthony B., Calgary, CANADA
Alcantara, Joenel, Calgary, CANADA
Hutchins, Wendy A., Calgary, CANADA
PI US 2005106157 A1 20050519
AI US 2004-757720 A1 20040115 (10)
RLI Continuation-in-part of Ser. No. US 2001-880901, filed on 15 Jun 2001, GRANTED, Pat. No. US 6761914 Continuation-in-part of Ser. No. US 2000-577147, filed on 24 May 2000, GRANTED, Pat. No. US 6372234 Continuation-in-part of Ser. No. US 1999-448600, filed on 24 Nov 1999, GRANTED, Pat. No. US 6183762 Continuation-in-part of Ser. No. US 1998-84777, filed on 27 May 1998, GRANTED, Pat. No. US 6146645
PRAI US 1998-75863P 19980225 (60)
US 1998-75864P 19980225 (60)
US 1997-47779P 19970528 (60)
US 1997-47753P 19970527 (60)
US 2000-212130P 20000616 (60)
DT Utility
FS APPLICATION
LREP BERESKIN AND PARR, 40 KING STREET WEST, BOX 401, TORONTO, ON, M5H 3Y2, CA
CLMN Number of Claims: 7

ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel adjuvants which comprise oil bodies. The invention also provides vaccine or immunogenic formulations comprising oil bodies and an antigen and methods for preparing the vaccine or immunogenic formulations and the use of the vaccine or immunogenic formulations to elicit an immune response.

L12 ANSWER 42 OF 98 USPATFULL on STN
AN 2005:98574 USPATFULL
TI Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
IN Wilder, Ronald L., Derwood, MD, UNITED STATES
Mao, Su-Yau, Gaithersburg, MD, UNITED STATES
PI US 2005084489 A1 20050421
AI US 2003-379145 A1 20030304 (10)
PRAI US 2002-361859P 20020304 (60)
US 2002-370398P 20020405 (60)
US 2003-444265P 20030130 (60)
US 2003-444156P 20030130 (60)
DT Utility
FS APPLICATION
LREP JOHNATHAN KLEIN-EVANS, ONE MEDIMMUNE WAY, GAITHERSBURG, MD, 20878, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an integrin α.sub.vβ.sub.3 antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an integrin α.sub.vβ.sub.3 antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphophonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin α.sub.vβ.sub.3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin α.sub.vβ.sub.3, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith, utilizing an antibody that immunospecifically binds to integrin α.sub.vβ.sub.3 (e.g., VITAXIN®) in combination with an HMG-CoA reductase inhibitor and/or bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin α.sub.vβ.sub.3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin α.sub.vβ.sub.3, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith.

L12 ANSWER 43 OF 98 USPATFULL on STN
AN 2005:90830 USPATFULL

TI Stabilized uncoated particles of reversed liquid crystalline phase materials
IN Anderson, David, Ashland, VA, UNITED STATES
PI US 2005077497 A1 20050414
AI US 2004-889313 A1 20040713 (10)
PRAI US 2003-509255P 20031008 (60)
DT Utility
FS APPLICATION
LREP Whitham, Curtis & Christofferson, PC, Suite 305, 11491 Sunset Hills Road, Reston, VA, 20190, US
CLMN Number of Claims: 200
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 3889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.

L12 ANSWER 44 OF 98 USPATFULL on STN
AN 2005:63801 USPATFULL
TI Proteases producing an altered immunological response and methods of making and using the same
IN Estell, David A, San Mateo, CA, UNITED STATES
Harding, Fiona A., Santa Clara, CA, UNITED STATES
Poulose, Ayrookaran J., Belmont, CA, UNITED STATES
PI US 2005054843 A1 20050310
AI US 2004-498694 A1 20040614 (10)
WO 2002-US41201 20021220
PRAI US 2001-344657P 20011231 (60)
DT Utility
FS APPLICATION
LREP Kamrin T MacKnight, Genencor International Inc, 925 Page Mill Road, Palo Alto, CA, 94304
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 3283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.

L12 ANSWER 45 OF 98 USPATFULL on STN
AN 2005:63585 USPATFULL
TI Cyclic derivatives as modulators of chemokine receptor activity
IN Carter, Percy H., Princeton, NJ, UNITED STATES
Cherney, Robert J., Newtown, PA, UNITED STATES
Batt, Douglas G., Wilmington, DE, UNITED STATES
Duncia, John V., Newtown, PA, UNITED STATES
Gardner, Daniel S., Furlong, PA, UNITED STATES
Ko, Soo S., Hockessin, DE, UNITED STATES
Srivastava, Anurag S., Belle Mead, NJ, UNITED STATES
Yang, Michael G., Narberth, PA, UNITED STATES
PI US 2005054627 A1 20050310
AI US 2004-923619 A1 20040819 (10)
PRAI US 2003-496947P 20030821 (60)

DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes modulators of MCP-1 of formula (I): ##STR1##

or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

L12 ANSWER 46 OF 98 USPATFULL on STN
AN 2005:63584 USPATFULL
TI Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
IN Carter, Percy H., Princeton, NJ, UNITED STATES
Cherney, Robert J., Newtown, PA, UNITED STATES
Batt, Douglas G., Wilmington, DE, UNITED STATES
Brown, Gregory D., Lansdale, PA, UNITED STATES
Duncia, John V., Newtown, PA, UNITED STATES
Gardner, Daniel S., Furlong, PA, UNITED STATES
Yang, Michael G., Narberth, PA, UNITED STATES
PI US 2005054626 A1 20050310
AI US 2004-923538 A1 20040819 (10)
PRAI US 2003-496974P 20030821 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes modulators of MCP-1 of formula (I): ##STR1##

or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

L12 ANSWER 47 OF 98 USPATFULL on STN
AN 2005:22829 USPATFULL
TI Controlled release bioactive agent delivery device
IN Anderson, Aron B., Minnetonka, MN, UNITED STATES
Lawin, Laurie R., New Brighton, MN, UNITED STATES
Shen, Byron C., Eden Prairie, MN, UNITED STATES
Juan, Eugene de, La Canada, CA, UNITED STATES
Varner, Signe E., Los Angeles, CA, UNITED STATES
PI US 2005019371 A1 20050127
AI US 2004-835530 A1 20040429 (10)
PRAI US 2003-467419P 20030502 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)

LN.CNT 2385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a controlled release bioactive agent delivery device that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent, wherein the first polymer comprises polyalkyl(meth)acrylate, aromatic poly(meth)acrylate, or a combination of polyalkyl(meth)acrylate and aromatic poly(meth)acrylate, and wherein the second polymer comprises poly(ethylene-co-vinyl acetate). The invention also provides methods of delivering a bioactive agent to a patient in a controlled release manner, as well as methods of making a controlled release bioactive agent delivery device.

L12 ANSWER 48 OF 98 USPATFULL on STN
AN 2004:320591 USPATFULL
TI Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
IN Shelton, David L., Oakland, CA, UNITED STATES
Vergara, German J., Moraga, CA, UNITED STATES
Loo, Carole M., San Mateo, CA, UNITED STATES
PI US 2004253244 A1 20041216
AI US 2004-783730 A1 20040219 (10)
PRAI US 2003-448823P 20030219 (60)
US 2003-448853P 20030219 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

L12 ANSWER 49 OF 98 USPATFULL on STN
AN 2004:189729 USPATFULL
TI Therapeutic and cosmetic uses of heparanases
IN Ilan, Neta, Rehovot, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Yacoby-Zeevi, Oron, Moshav Bizaron, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PI US 2004146497 A1 20040729
AI US 2004-781758 A1 20040220 (10)
RLI Continuation of Ser. No. US 2003-341582, filed on 14 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001, PENDING Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001, PENDING Continuation of Ser. No. US 1999-258892, filed on 1 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, GRANTED, Pat. No. US 5968822 Continuation-in-part of Ser. No. WO 2001-IL830, filed on 5 Sep 2001, UNKNOWN
PRAI US 2000-244593P 20001101 (60)
US 2000-231551P 20000911 (60)
DT Utility

FS APPLICATION
LREP SOL SHEINBEIN, c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN 49 Drawing Page(s)
LN.CNT 5685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.

L12 ANSWER 50 OF 98 USPATFULL on STN
AN 2004:171456 USPATFULL
TI Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
IN Shelton, David L., Oakland, CA, UNITED STATES
Vergara, German J., Moraga, CA, UNITED STATES
PI US 2004131615 A1 20040708
AI US 2003-682332 A1 20031008 (10)
PRAI US 2002-417347P 20021008 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist and an amount of an opioid analgesic such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an opioid analgesic and kits containing the same.

L12 ANSWER 51 OF 98 USPATFULL on STN
AN 2004:150914 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2004115135 A1 20040617
AI US 2002-322266 A1 20021217 (10)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 94
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 9307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the

peptide YY to the subject by subcutaneous injection.

L12 ANSWER 52 OF 98 USPATFULL on STN
AN 2004:114702 USPATFULL
TI Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Attar, Ricardo M., Lawrenceville, NJ, UNITED STATES
Gottardis, Marco M., Princeton, NJ, UNITED STATES
Balog, James Aaron, Scotch Plains, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Martinez, Rogelio L., Monmouth Junction, NJ, UNITED STATES
Sun, Chongping, East Windsor, NJ, UNITED STATES
PI US 2004087548 A1 20040506
AI US 2002-75870 A1 20020214 (10)
PRAI US 2001-271672P 20010227 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 53 OF 98 USPATFULL on STN
AN 2004:101736 USPATFULL
TI Fused cyclic modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Shan, Weifang, Princeton, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Harikrishnan, Lalgudi S., Princeton, NJ, UNITED STATES
PI US 2004077606 A1 20040422
US 7001911 B2 20060221
AI US 2002-322306 A1 20021218 (10)
RLI Continuation-in-part of Ser. No. US 2001-25233, filed on 19 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-885798, filed on 20 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885827, filed on 20 Jun 2001, PENDING
PRAI US 2000-214392P 20000628 (60)
US 2001-284438P 20010418 (60)
US 2001-284617P 20010418 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 54 OF 98 USPATFULL on STN
AN 2004:101735 USPATFULL

TI Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Fura, Aberra, Lawrenceville, NJ, UNITED STATES
Li, Wenying, Middletown, CT, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
Mitt, Toomas, Plainsboro, NJ, UNITED STATES
Roberge, Jacques Y., Princeton, NJ, UNITED STATES
Corte, James R., Lawrenceville, NJ, UNITED STATES
Spergel, Steven H., Warrington, PA, UNITED STATES
Rampulla, Richard A., Flemington, NJ, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Xiao, Hai-Yun, Princeton, NJ, UNITED STATES
PI US 2004077605 A1 20040422
AI US 2002-322077 A1 20021218 (10)
RLI Continuation-in-part of Ser. No. US 2001-25116, filed on 19 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885381, filed on 20 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-885827, filed on 20 Jun 2001, PENDING
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 55 OF 98 USPATFULL on STN
AN 2004:101725 USPATFULL
TI Cyclodextrin-based polymers for therapeutics delivery
IN Cheng, Jianjun, Arcadia, CA, UNITED STATES
Davis, Mark E., Pasadena, CA, UNITED STATES
Khin, Kay T., San Gabriel, CA, UNITED STATES
PA Insert Therapeutics, Inc., Pasadena, CA, UNITED STATES (U.S. corporation)
PI US 2004077595 A1 20040422
AI US 2003-656838 A1 20030905 (10)
PRAI US 2002-408855P 20020906 (60)
US 2002-422830P 20021031 (60)
US 2003-451998P 20030304 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4117
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker

groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

L12 ANSWER 56 OF 98 USPATFULL on STN
AN 2004:101671 USPATFULL
TI Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004077540 A1 20040422
AI US 2003-601953 A1 20030624 (10)
PRAI US 2002-392512P 20020628 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 13170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.

L12 ANSWER 57 OF 98 USPATFULL on STN
AN 2004:88227 USPATFULL
TI Targeted therapeutic lipid constructs
IN Brunke, Karen J., Belmont, CA, UNITED STATES
Wartchow, Charles A., San Francisco, CA, UNITED STATES
Cleland, Jeffrey L., San Carlos, CA, UNITED STATES
PI US 2004067196 A1 20040408
AI US 2003-401280 A1 20030327 (10)
RLI Continuation-in-part of Ser. No. US 2001-976254, filed on 11 Oct 2001, PENDING
PRAI US 2000-239684P 20001011 (60)
US 2002-367858P 20020327 (60)
DT Utility
FS APPLICATION
LREP SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel therapeutic lipid constructs comprising a lipid construct, an

anti-cell surface targeting agent, and a radiotherapeutic metal ion are disclosed.

L12 ANSWER 58 OF 98 USPATFULL on STN
AN 2004:50383 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of interferon beta
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Gupta, Malini, Dix Hills, NY, UNITED STATES
de Meireles, Jorge C., Syosset, NY, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004037809 A1 20040226
AI US 2003-462452 A1 20030616 (10)
PRAI US 2002-393066P 20020628 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-β and/or a substantially decreased time to maximal concentration of interferon-β in a tissue of a subject as compared to controls where the interferon-β is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-β according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

L12 ANSWER 59 OF 98 USPATFULL on STN
AN 2004:44283 USPATFULL
TI Withasol and methods of use
IN Patwardhan, Bhushan, Pune, INDIA
Kapadi, Aravind H., Pune, INDIA
PA AyurCore, Inc., San Jose, CA (non-U.S. corporation)
PI US 2004033273 A1 20040219
AI US 2002-74146 A1 20020111 (10)
PRAI US 2001-269214P 20010214 (60)
DT Utility
FS APPLICATION
LREP Pillsbury Winthrop LLP, Suite 1800, 101 W. Broadway, San Diego, CA, 92101
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions useful for ameliorating or reversing naturally occurring immunosuppression or myelosuppresive, or side effects of myelosuppresive or immunosuppresive drug therapy. Medicinal fractions derived from the plant Withania Somnifera that reverse, at least in part, one or more characteristics of immunosuppression or myelosuppression and a process for manufacturing the fractions are particular aspects of the invention. Withania

Somnifera medicinal fractions have additional biological activities including anti-tumor potentiating activity.

L12 ANSWER 60 OF 98 USPATFULL on STN
AN 2004:38077 USPATFULL
TI Dopamine agonist formulations for enhanced central nervous system delivery
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)
PI US 2004028613 A1 20040212
AI US 2001-891630 A1 20010625 (9)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 8045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous sytstem (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

L12 ANSWER 61 OF 98 USPATFULL on STN
AN 2004:30732 USPATFULL
TI Methods and compositions for modulating the immune system and uses thereof
IN Chen, Lan Bo, Lexington, MA, UNITED STATES
Kraeft, Stine-Kathrein, Dorchester, MA, UNITED STATES
Auclair, Daniel, Ashland, MA, UNITED STATES
PI US 2004022869 A1 20040205
AI US 2002-307916 A1 20021202 (10)
PRAI US 2001-334121P 20011130 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 49
ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)
LN.CNT 5354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of preventing, treating or ameliorating one or more symptoms of disorders in which modulation of a subject's immune system is beneficial utilizing a lymphoid tissue inducing agent and an immunomodulatory agent. In particular, the present invention provides methods of preventing, treating or ameliorating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more lymphoid tissue inducing agents and one or immunomodulatory agents. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to proliferative disorders, infectious diseases, cardiovascular diseases, autoimmune disorders and inflammatory disorders. The present invention further provides methods for screening and identifying lymphoid tissue inducing agents and/or immunomodulatory agents.

L12 ANSWER 62 OF 98 USPATFULL on STN
AN 2004:12708 USPATFULL
TI Injectable system for controlled drug delivery
IN McHugh, Anthony J., Urbana, IL, UNITED STATES
DesNoyer, Jessica R., Santa Clara, CA, UNITED STATES
PI US 2004009226 A1 20040115
AI US 2002-191789 A1 20020709 (10)
DT Utility
FS APPLICATION
LREP BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60611
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1086
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An injectable composition for delivery of a bioactive agent contains a biocompatible solvent, a hydrophobic polymer, and an amphiphilic block copolymer. The hydrophobic polymer may be a biodegradable polymer, and the block copolymer may contain a segment of poly(ethylene oxide).

L12 ANSWER 63 OF 98 USPATFULL on STN
AN 2004:4510 USPATFULL
TI Human tumor-associated gene
IN Hoon, David S. B., Los Angeles, CA, United States
PA John Wayne Cancer Institute, Santa Monica, CA, United States (U.S. corporation)
PI US 6673914 B1 20040106
AI US 1999-234685 19990121 (9)
PRAI US 1998-72126P 19980122 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Helms, Larry
LREP Fulbright & Jaworski
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 5257
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a novel tumor marker antigen encoded by a gene designated as HOJ-1 (SEQ ID NO:1). In specific embodiment, the nucleic acid sequences disclosed herein are for used in the diagnosis and prognosis of cancer. Also provided are related protein and antibody compositions and various methods of use thereof, including methods for

cancer diagnosis and treatment.

L12 ANSWER 64 OF 98 USPATFULL on STN
AN 2003:321350 USPATFULL
TI Emulsion vehicle for poorly soluble drugs
IN Lambert, Karel J., Woodinville, WA, United States
Constantinides, Panayiotis P., Bothell, WA, United States
Tustian, Alexander K., Bothell, WA, United States
Quay, Steven C., Edmonds, WA, United States
PA Sonus Pharmaceuticals, Inc., Bothell, WA, United States (U.S. corporation)
PI US 6660286 B1 20031209
AI US 1999-317499 19990524 (9)
RLI Continuation-in-part of Ser. No. US 1998-3173, filed on 5 Jan 1998
PRAI US 1997-48840P 19970606 (60)
US 1997-34188P 19970107 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Webman, Edward J.
LREP Christensen O'Connor Johnson Kindness PLLC
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 2047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated α-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of α-tocopherol.

L12 ANSWER 65 OF 98 USPATFULL on STN
AN 2003:318714 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
IN Barber, Lauren E., Higganum, CT, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
Neubauer, Michael G., Skillman, NJ, UNITED STATES
Kornacker, Michael G., Princeton, NJ, UNITED STATES
PI US 2003224458 A1 20031204
AI US 2003-375157 A1 20030226 (10)
RLI Continuation-in-part of Ser. No. US 2001-10568, filed on 7 Dec 2001, PENDING
PRAI US 2000-251926P 20001207 (60)
US 2001-269795P 20010214 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 14624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY23 polypeptides, fragments and homologues thereof. Also provided are

vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY23 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly renal diseases and/or disorders, colon cancer, breast cancer, and diseases and disorders related to aberrant NFKB modulation. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L12 ANSWER 66 OF 98 USPATFULL on STN
AN 2003:318656 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
IN Barber, Lauren E., Higganum, CT, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bol, David K., Gaithersburg, MD, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
PI US 2003224400 A1 20031204
AI US 2003-369405 A1 20030214 (10)
RLI Continuation-in-part of Ser. No. US 2001-991225, filed on 16 Nov 2001, PENDING
PRAI US 2000-249613P 20001117 (60)
US 2000-257611P 20001221 (60)
US 2001-305818P 20010716 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 15695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders, ovarian cancer, and diseases and disorders related to aberrant NFKB modulation. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L12 ANSWER 67 OF 98 USPATFULL on STN
AN 2003:271481 USPATFULL
TI C3-CYANO EPOTHILONE DERIVATIVES
IN Regueiro-Ren, Alicia, Middletown, CT, UNITED STATES
Kim, Soong-Hoon, Titusville, NJ, UNITED STATES
PI US 2003191089 A1 20031009
US 6719540 B2 20040413
AI US 2003-386072 A1 20030311 (10)
PRAI US 2002-363441P 20020312 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by formula I: ##STR1##

wherein:

Q is selected from the group consisting of ##STR2##

M is O, NR.sub.9, or CR.sub.10R.sub.11; X is O or NH; and the R groups are as defined, and therapeutic compositions containing them alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases.

L12 ANSWER 68 OF 98 USPATFULL on STN
AN 2003:231625 USPATFULL
TI Therapeutic and cosmetic uses of heparanases
IN Ilan, Neta, Rehovot, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Yacoby-Zeevi, Oron, Moshav Bizaron, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PI US 2003161823 A1 20030828
AI US 2003-341582 A1 20030114 (10)
RLI Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001, PENDING Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001, PENDING Continuation of Ser. No. US 1999-258892, filed on 1 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31 Aug 1998, PENDING Continuation-in-part of Ser. No. WO 2001-IL830, filed on 5 Sep 2001, UNKNOWN
DT Utility
FS APPLICATION
LREP G.E. EHRLICH (1995) LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN 49 Drawing Page(s)
LN.CNT 7437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.

L12 ANSWER 69 OF 98 USPATFULL on STN
AN 2003:195087 USPATFULL
TI Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
IN Homan, Reynold, Ann Arbor, MI, UNITED STATES
PI US 2003134898 A1 20030717
AI US 2002-209236 A1 20020731 (10)
PRAI US 2001-309336P 20010801 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of inhibiting sebum production

and treating sebaceous gland disorders comprising administering to a patient in need of said treatment an effective amount of a compound that inhibits both acyl-Coenzyme A:cholesteryl acyltransferase (ACAT), and acyl-Coenzyme A:fatty alcohol acyltransferase (AFAT), provided that the compound is not [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt or solvate thereof. The method of the invention is useful to treat sebaceous gland disorders caused or exacerbated by the overproduction of sebum, including oily skin, acne, seborrhea, perioral dermatitis, rosacea, and corticosteroid-induced acneiform lesions.

L12 ANSWER 70 OF 98 USPATFULL on STN
AN 2003:166562 USPATFULL
TI Fused cyclic modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Shan, Weifang, Princeton, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
PI US 2003114420 A1 20030619
AI US 2001-25233 A1 20011219 (10)
RLI Continuation-in-part of Ser. No. US 2001-885798, filed on 20 Jun 2001, ABANDONED
PRAI US 2000-214392P 20000628 (60)
US 2001-284617P 20010418 (60)
US 2001-284438P 20010418 (60)
DT Utility
FS APPLICATION
LREP Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

L12 ANSWER 71 OF 98 USPATFULL on STN
AN 2003:166044 USPATFULL
TI Methods of preserving prokaryotic cells and compositions obtained thereby
IN Tunnacliffe, Alan G., Horningsea, UNITED KINGDOM
Welsh, David T., Stanley, UNITED KINGDOM
Roser, Bruce J., Cambridge, UNITED KINGDOM
Dhaliwal, Kamaljit S., Hitchin, UNITED KINGDOM
Colaco, Camilo, Cambridge, UNITED KINGDOM
PI US 2003113900 A1 20030619
AI US 2002-215060 A1 20020807 (10)
RLI Continuation of Ser. No. US 1997-985343, filed on 4 Dec 1997, GRANTED, Pat. No. US 6468782
PRAI US 1996-32423P 19961205 (60)
DT Utility
FS APPLICATION
LREP Madeline I. Johnston, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1646
AB This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce

intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.

L12 ANSWER 72 OF 98 USPATFULL on STN
AN 2003:159960 USPATFULL
TI Emulsion vehicle for poorly soluble drugs
IN Lambert, Karel J., Woodinville, WA, UNITED STATES
Tustian, Alexander K., Bothell, WA, UNITED STATES
Quay, Steven C., Edmonds, WA, UNITED STATES
PA Sonus Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003109575 A1 20030612
AI US 2002-187055 A1 20020628 (10)
RLI Continuation of Ser. No. US 1999-317499, filed on 24 May 1999, PENDING Continuation-in-part of Ser. No. US 1998-3173, filed on 5 Jan 1998, GRANTED, Pat. No. US 6458373
PRAI US 1997-48840P 19970606 (60)
US 1997-34188P 19970107 (60)
DT Utility
FS APPLICATION
LREP CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC, 1420 FIFTH AVENUE, SUITE 2800, SEATTLE, WA, 98101-2347
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated α-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of α-tocopherol.

L12 ANSWER 73 OF 98 USPATFULL on STN
AN 2003:112567 USPATFULL
TI Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Venkateshwaran, Srinivasan, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Park City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
PI US 2003077297 A1 20030424
AI US 2002-74687 A1 20020211 (10)
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, PENDING Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 145
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to pharmaceutical formulations and

systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.

L12 ANSWER 74 OF 98 USPATFULL on STN
AN 2003:93663 USPATFULL
TI Emulsion vehicle for poorly soluble drugs
IN Lambert, Karel J., Woodinville, WA, UNITED STATES
Constantinides, Panayiotis P., Bothell, WA, UNITED STATES
Tustian, Alexander K., Bothell, WA, UNITED STATES
Quay, Steven C., Edmonds, WA, UNITED STATES
PA Sonus Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003065024 A1 20030403
US 7030155 B2 20060418
AI US 2002-151066 A1 20020517 (10)
RLI Continuation of Ser. No. US 1999-317495, filed on 24 May 1999, PENDING
PRAI US 1998-88269P 19980605 (60)
DT Utility
FS APPLICATION
LREP CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC, 1420 FIFTH AVENUE, SUITE 2800, SEATTLE, WA, 98101-2347
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of making an emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated α-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of α-tocopherol.

L12 ANSWER 75 OF 98 USPATFULL on STN
AN 2003:85864 USPATFULL
TI Preparations and processes for stabilizing biological materials by means of drying processes without freezing
IN Mattern, Markus, Heppenheim, GERMANY, FEDERAL REPUBLIC OF
Winter, Gerhard, Dossenheim, GERMANY, FEDERAL REPUBLIC OF
PA Roche Diagnostics GmbH (non-U.S. corporation)
PI US 2003059468 A1 20030327
AI US 2002-141960 A1 20020510 (10)
RLI Division of Ser. No. US 1998-51918, filed on 27 Apr 1998, PENDING A 371 of International Ser. No. WO 1996-EP4627, filed on 24 Oct 1996, UNKNOWN
PRAI DE 1995-19539574 19951025
DT Utility
FS APPLICATION
LREP ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE 400, WASHINGTON, DC, 20036
CLMN Number of Claims: 28
ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)
LN.CNT 1510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups

(i) carbohydrate or zwitterion with a polar residue and derivatives thereof, and

(ii) zwitterion with an apolar residue and derivatives thereof,

wherein a solution is prepared of the biologically or therapeutically active material and of substances (i) and (ii) and the solution is dried at a product temperature above the freezing point of the solution. In addition the invention concerns new substance mixtures which are obtained by the said process as well as the use thereof in diagnostic or therapeutic methods.

L12 ANSWER 76 OF 98 USPATFULL on STN
AN 2003:85799 USPATFULL
TI Aquespheres, their preparation and uses thereof
IN Jin, Tuo, Highland Park, NJ, UNITED STATES
Zhu, Hua, Plainsboro, NJ, UNITED STATES
Zhu, Jiahao, Brooklyn, NY, UNITED STATES
PI US 2003059402 A1 20030327
US 6998393 B2 20060214
AI US 2002-291327 A1 20021108 (10)
PRAI WO 2001-CN1033 20010622
US 2002-384971P 20020603 (60)
US 2002-418100P 20021011 (60)
DT Utility
FS APPLICATION
LREP Albert Wai-Kit Chan, Law Offices of Albert Wai-Kit Chan, LLC, World Plaza, Suite 604, 141-07 20th Avenue, Whitestone, NY, 11357
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (Stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysacchride glassy particles under a condition free of any chemical or physical hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and cross-linking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the technical challenges raised in sustained release delivery of proteins.

L12 ANSWER 77 OF 98 USPATFULL on STN
AN 2003:57103 USPATFULL
TI Anti-fungal composition
IN Jira, Vic, El Monte, CA, UNITED STATES
Jirathitikal, Vichai, Chachoengsao, THAILAND
PI US 2003039667 A1 20030227
AI US 2002-228280 A1 20020827 (10)
PRAI US 2001-314666P 20010827 (60)

DT Utility
FS APPLICATION
LREP BLANK ROME COMISKY & MCCAULEY, LLP, 900 17TH STREET, N.W., SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multivalent fungal vaccine comprising one or more heat-inactivated fungal antigens, wherein at least one fungal antigen is effective in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the fungal disease in said host. Also described are methods for making and using an orally available anti-fungal vaccine.

L12 ANSWER 78 OF 98 USPATFULL on STN
AN 2003:57050 USPATFULL
TI Process for preparing a pharmaceutical composition
IN Busson, Patrick, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Schroeder, Marco, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2003039614 A1 20030227
US 7074431 B2 20060711
AI US 2002-266363 A1 20021008 (10)
RLI Continuation of Ser. No. US 2001-891069, filed on 25 Jun 2001, PENDING
PRAI EP 2000-113535 20000627
DT Utility
FS APPLICATION
LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 989
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

L12 ANSWER 79 OF 98 USPATFULL on STN
AN 2003:44355 USPATFULL
TI Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
IN Dang, Nam Hoang, Houston, TX, UNITED STATES
Morimoto, Chikao, Tokyo, JAPAN
Schlossman, Stuart, Newton Centre, MA, UNITED STATES
PI US 2003031665 A1 20030213
AI US 2002-143553 A1 20020510 (10)
PRAI US 2001-290531P 20010511 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS AVENUE, AUSTIN, TX, 78701-3271
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 3596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.

L12 ANSWER 80 OF 98 USPATFULL on STN
AN 2002:303656 USPATFULL
TI Phase change formulation
IN Malach, Ted J., 105 Appleglen Pl. SE., Calgary, CANADA T2A 7T4
PI US 6482332 B1 20021119
AI US 2000-523570 20000310 (9)
PRAI US 1999-124049P 19990312 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Green, Anthony J.
LREP Christensen O'Connor Johnson Kindness PLLC
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A thermal packaging system using a single phase change material (PCM) part in liquid and part in solid form to confine the temperature of the product within a predetermined range. The temperature ranges are determined by the selection of PCM formulation. The phase change materials selected have high latent heats of fusion and maintain relatively constant temperatures as they change phase. This permits light weight packaging with the maintenance of temperatures in narrow, preselected ranges over extended periods of time. A phase change formulation that can be adjusted to freeze at temperatures from +40° C. to below -30° C. is disclosed, comprising butanediol, selected percentages of distilled water, and nucleating agents. The phase change occurs over a narrow temperature range making this an ideal temperature control media. Nucleating or other agents are included to narrow the temperature range over which the phase change occurs.

L12 ANSWER 81 OF 98 USPATFULL on STN
AN 2002:301593 USPATFULL
TI Delivery vehicles for bioactive agents and uses thereof
IN Kunz, Lawrence L., Redmond, WA, UNITED STATES
Tice, Thomas R., Hoover, AL, UNITED STATES
Libby, Randell T., Redmond, WA, UNITED STATES
McDaniel, Christopher W., Hoover, AL, UNITED STATES
PA Southern Research Institute (U.S. corporation)
PI US 2002169138 A1 20021114
AI US 2002-73744 A1 20020211 (10)
RLI Continuation of Ser. No. US 1998-178438, filed on 23 Oct 1998, ABANDONED
PRAI US 1997-63114P 19971024 (60)
DT Utility
FS APPLICATION
LREP NEEDLE & ROSENBERG P C, 127 PEACHTREE STREET N E, ATLANTA, GA, 30303-1811
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for transporting a bioactive agent across a biological membrane include the bioactive agent, an oil, an oil-immiscible compound and a noncationic surface active agent. The compositions may deliver the bioactive agent through a chemical microporulation mechanism, which allows transfer of the agent across both cellular, intracellular

organelle, and nuclear membranes. Compositions for nucleic acid delivery include nucleic acid, oil, oil-immiscible compound, noncationic surface active agent and essentially no cationic lipid, or include nucleic acid, oil, oil-immiscible compound and two noncationic surface active agents. The nucleic acid may be hydrophobically-modified, and be in combination with an oil, an oil-immiscible compound and at least one surface active agent. The compositions may be used for gene delivery to a cell , as well as delivery of other therapeutic agents.

L12 ANSWER 82 OF 98 USPATFULL on STN
AN 2002:275930 USPATFULL
TI Methods of preserving prokaryotic cells and compositions obtained thereby
IN Tunnacliffe, Alan G., Horningsea, UNITED KINGDOM
Welsh, David T., Stanley, UNITED KINGDOM
Roser, Bruce J., Cambridge, UNITED KINGDOM
Dhaliwal, Kamaljit S., Hitchin, UNITED KINGDOM
Colaco, Camilo, Cambridge, UNITED KINGDOM
PA Quadrant Healthcare (UK) Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)
PI US 6468782 B1 20021022
AI US 1997-985343 19971204 (8)
PRAI US 1996-32423P 19961205 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saucier, Sandra E.
LREP Morrison & Forester LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 23
DRWN 10 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1687
AB This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.

L12 ANSWER 83 OF 98 USPATFULL on STN
AN 2002:152682 USPATFULL
TI Substituted cyclopentane compounds useful as neuraminidase inhibitors
IN Babu, Yarlagadda S., Birmingham, AL, United States
Chand, Pooran, Birmingham, AL, United States
Montgomery, John A., Birmingham, AL, United States
PA Biocryst Pharmaceuticals, Inc., Birmingham, AL, United States (U.S. corporation)
PI US 6410594 B1 20020625
WO 9747194 19971218
AI US 1999-202351 19990609 (9)
WO 1997-US9309 19970613
19990609 PCT 371 date
PRAI US 1996-19930P 19960614 (60)
US 1997-44010P 19970502 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Deemie, Robert W.
LREP Connolly Bove Lodge & Hutz LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds represented by formula (I), and pharmaceutically acceptacle salts thereof; and their method of preparation are provided. Compounds

of the above formula are influenza virus neuraminidase inhibitors and can be used in treating patients infected with influenza virus. ##STR1##

L12 ANSWER 84 OF 98 USPATFULL on STN
AN 2002:140865 USPATFULL
TI Vaccines comprising oil bodies
IN Deckers, Harm M., Alberta, CANADA
Rooijen, Gijs Van, Alberta, CANADA
Boothe, Joseph, Alberta, CANADA
Goll, Janis, Alberta, CANADA
Moloney, Maurice M., Alberta, CANADA
Schryvers, Anthony B., Alberta, CANADA
Alcantara, Joenel, Alberta, CANADA
Hutchins, Wendy A., Alberta, CANADA
PI US 2002071846 A1 20020613
US 6761914 B2 20040713
AI US 2001-880901 A1 20010615 (9)
RLI Continuation-in-part of Ser. No. US 2000-577147, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-448600, filed on 24 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1998-84777, filed on 27 May 1998, PATENTED
PRAI US 1998-75863P 19980225 (60)
US 1998-75864P 19980225 (60)
US 1997-47779P 19970528 (60)
US 1997-47753P 19970527 (60)
US 2000-212130P 20000616 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel adjuvants which comprise oil bodies. The invention also provides vaccine formulations comprising oil bodies and an antigen and methods for preparing the vaccines and the use of the vaccines to elicit an immune response.

L12 ANSWER 85 OF 98 USPATFULL on STN
AN 2002:98853 USPATFULL
TI STABILIZED WATER-IN-OIL-IN-WATER ANTIGEN DELIVERY SYSTEM
IN SNOW, WILLIAM C., WINSLOW, ME, UNITED STATES
GOGAN, WALTER C., WINSLOW, ME, UNITED STATES
PI US 2002051748 A1 20020502
AI US 1998-226525 A1 19981222 (9)
DT Utility
FS APPLICATION
LREP THOMAS L. BOHAN & ASSOCIATES, 371 FORE STREET, SUITE 202, PORTLAND, ME, 04101
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A water-in-oil-in-water (W/O/W) emulsion to be used in an antigen delivery system to induce rapid and long-lasting immunity among populations of livestock, birds, and fish. The external aqueous phase of the W/O/W emulsion contains a thixotropic inorganic salt, such as aluminum hydroxide or alum. The presence of the inorganic salt helps to elicit both a Th1 and a Th2 response from the subject's immune system,

and the thixotropic properties of the salt stabilize the water-in-oil-in-water emulsion, thereby providing a longer vaccine shelf life. The antigen dose to be delivered to the subject may be contained in entirely in the internal aqueous phase. Alternatively, a first portion of the total antigen dose may be included in the internal aqueous phase and a second portion is included in the external aqueous phase. The incorporation of a portion of the antigen in the external aqueous phase triggers a more uniform immune response across a vaccinated population. The W/O/W based vaccines can be administered either by injection or orally.

L12 ANSWER 86 OF 98 USPATFULL on STN
AN 2002:92627 USPATFULL
TI Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors
IN Murphy, Evelyn, Dublin, IRELAND
Conneely, Orla M., Houston, TX, UNITED STATES
Fitzgerald, Oliver, Dublin, IRELAND
Bresnihan, Barry, Dublin, IRELAND
PI US 2002049151 A1 20020425
AI US 2001-853386 A1 20010511 (9)
PRAI US 2000-203645P 20000512 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 3922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synovial CRH functions in a paracrine manner to induce the nuclear transcription factor NURR1, which is abundantly expressed in the inflammatory cells of both rheumatoid arthritis and psoriatic arthritis synovium. This induction is suppressed by glucocorticoids. The invention is directed to the pivotal role the NURR subfamily of transcription factors plays in modulation of peripheral CRH and CRH-mediated signaling through the CRH-receptor subtype R1α, particularly in the inflammatory process in human arthritis.

L12 ANSWER 87 OF 98 USPATFULL on STN
AN 2002:31991 USPATFULL
TI Process for preparing a pharmaceutical composition
IN Busson, Patrick, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Schroeder, Marco, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2002018812 A1 20020214
US 6534087 B2 20030318
AI US 2001-891069 A1 20010625 (9)
PRAI EP 2000-113535 20000627
DT Utility
FS APPLICATION
LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more

pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

L12 ANSWER 88 OF 98 USPATFULL on STN
AN 2001:22018 USPATFULL
TI Method of inactivation of viral and bacterial blood contaminants
IN Platz, Matthew S., Columbus, OH, United States
Goodrich, Jr., Raymond P., Pasadena, CA, United States
Yerram, Nagender, South Pasadena, CA, United States
PA Baxter International Inc., Deerfield, IL, United States (U.S. corporation)
PI US 6187572 B1 20010213
AI US 1993-47749 19930414 (8)
RLI Continuation-in-part of Ser. No. US 1992-825691, filed on 27 Jan 1992, now abandoned Continuation-in-part of Ser. No. US 1991-685931, filed on 16 Apr 1991, now abandoned Continuation-in-part of Ser. No. US 1991-656254, filed on 15 Feb 1991, now abandoned Continuation-in-part of Ser. No. US 1990-632277, filed on 20 Dec 1990, now abandoned Continuation-in-part of Ser. No. US 1990-510234, filed on 16 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Weber, Jon P.
LREP Swanson, Barry J., Serewicz, Denise M., Price, Bradford R. L.
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 2112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for inactivating viral and/or bacterial contamination in blood cellular matter, such as erythrocytes and platelets, or protein fractions. The cells or protein fractions are mixed with chemical sensitizers, frozen or freeze-dried, and irradiated with, for example, UV, visible, gamma or X-ray radiation while in the solid state.

L12 ANSWER 89 OF 98 USPATFULL on STN
AN 2001:18010 USPATFULL
TI Oil body based personal care products
IN Deckers, Harm M., Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PA Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)
PI US 6183762 B1 20010206
AI US 1999-448600 19991124 (9)
RLI Continuation-in-part of Ser. No. US 1998-84777, filed on 27 May 1998
PRAI US 1997-47753P 19970527 (60)
US 1997-47779P 19970528 (60)
US 1998-75863P 19980225 (60)
US 1998-75864P 19980225 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dodson, Shelley A.; Assistant Examiner: Lamm, Marina
LREP Bereskin & Parr
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel emulsion formulations which

comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

L12 ANSWER 90 OF 98 USPATFULL on STN
AN 97:122866 USPATFULL
TI Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
IN Cha, Younsik, Salt Lake City, UT, United States
Choi, Young Kweon, Salt Lake City, UT, United States
Bae, You Han, Kwangju, Korea, Republic of
PA Macromed, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 5702717 19971230
AI US 1995-548185 19951025 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dean, Ralph H.
LREP Thorpe, North & Western, L.L.P.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A system and method for the parenteral delivery of a drug in a biodegradable polymeric matrix to a warm blooded animal as a liquid with the resultant formation of a gel depot for the controlled release of the drug. The system comprises an injectable biodegradable block copolymeric drug delivery liquid having reverse thermal gelation properties. The delivery liquid is an aqueous solution having dissolved or dispersed therein an effective amount of a drug intimately contained in a biodegradable block copolymer matrix. The copolymer has a reverse gelation temperature below the body temperature of the animal to which it is administered and is made up of (i) a hydrophobic A polymer block comprising a member selected from the group consisting of poly(α-hydroxy acids) and poly(ethylene carbonates) and (ii) a hydrophilic B polymer block comprising a polyethylene glycol. Prior to use the liquid is maintained at a temperature below the reverse gelation temperature of the block copolymer. The liquid is parenterally administered into the animal by intramuscular, intraperitoneal, subcutaneous or similar injection with the liquid forming a gel depot of the drug and biodegradable block polymer as the temperature of the liquid is raised by the body temperature of the animal the reverse gelation temperature of the block copolymer. The drug is released at a controlled rate from the copolymer which biodegrades into non-toxic products. The degradation rate can be adjusted by proper selection of the poly(α-hydroxy acid) utilized in forming the biodegradable hydrophilic A block.

L12 ANSWER 91 OF 98 USPATFULL on STN
AN 97:112440 USPATFULL
TI Method of administering a biologically active substance
IN Bechgaard, Erik, Hellerup, Denmark
Gizurarson, Sveinbjorn, Keflavik, Iceland
Hjortkj.ae butted.r, Rolf Kuhlman, Humleb.ae butted.r, Denmark
PA Bechgaard International Research and Development A/S, Hellerup, Denmark (non-U.S. corporation)
PI US 5693608 19971202
AI US 1995-395838 19950228 (8)
RLI Continuation of Ser. No. US 1993-151802, filed on 15 Nov 1993, now patented, Pat. No. US 5428006 which is a continuation of Ser. No. US 1993-71604, filed on 4 Jun 1993, now abandoned which is a continuation of Ser. No. US 1992-870893, filed on 20 Apr 1992, now abandoned which is

a division of Ser. No. US 1991-696564, filed on 8 May 1991, now abandoned
PRAI DK 1990-1170 19900510
DK 1990-2075 19900830
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
LREP Evenson, McKeown, Edwards & Lenahan P.L.L.C.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 1823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for administering a therapeutically effective amount of a biologically active substance to the circulatory system of a mammal including administering a pharmaceutical composition having a total volume of 1-1000 μl to a nasal mucosal membrane of the mammal, the pharmaceutical composition including the therapeutically effective amount of the biologically active substance dissolved or suspended in a volume of 1-1000 μl of an n-ethylene glycol containing vehicle including at least one n-ethylene glycol represented by the formula:

H(OCH.sub.2 CH.sub.2).sub.p OH

wherein p is from 1 to 8, so that upon administration of the pharmaceutical composition to the nasal mucosal membrane, absorption of the biologically active substance through the mucosal membrane and into the blood stream of the mammal rapidly takes place and thereby allows the biologically active substance to exert its therapeutic effect.

L12 ANSWER 92 OF 98 USPATFULL on STN
AN 97:17918 USPATFULL
TI Compositions and methods for enhanced drug delivery
IN Hale, Ron L., Woodside, CA, United States
Lu, Amy, Los Altos, CA, United States
Solas, Dennis, San Francisco, CA, United States
Selick, Harold E., Belmont, CA, United States
Oldenburg, Kevin R., Fremont, CA, United States
Zaffaroni, Alejandro C., Atherton, CA, United States
PA Affymax Technologies N.V., Middlesex, England (non-U.S. corporation)
PI US 5607691 19970304
AI US 1995-449188 19950524 (8)
RLI Continuation of Ser. No. US 1993-164293, filed on 9 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-77296, filed on 14 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-898219, filed on 12 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-9463, filed on 27 Jan 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Levy, Neil S.
LREP Stevens, Lauren L.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

L12 ANSWER 93 OF 98 USPATFULL on STN

AN 97:12613 USPATFULL
TI Substituted benzene derivatives useful as neuraminidase inhibitors
IN Babu, Yarlagadda S., Birmingham, AL, United States
Chand, Pooran, Birmingham, AL, United States
Walsh, David A., Birmingham, AL, United States
PA BioCryst Pharmaceuticals, Inc., Birmingham, AL, United States (U.S. corporation)
PI US 5602277 19970211
AI US 1995-413886 19950330 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Frazier, Barbara S.
LREP Pollock, Vande Sande & Priddy
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2712
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the Formula (I): ##STR1## or pharmaceutically-suitable salts or prodrug forms thereof, wherein: n is 0-1;

m is 0;

p is 0-1;

R.sup.1 is --CO.sub.2 H;

R.sup.2 is selected from the group consisting of H, --OH, and --NH.sub.2 ;

R.sup.3 is H;

R.sup.4 is --C(O)NHR.sup.8 ;

R.sup.5 is --NHC(R.sup.6)NH.sub.2

R.sup.6 is selected from the group consisting of .dbd.NH, .dbd.NOH, .dbd.NCN, .dbd.O, and .dbd.S; and

R.sup.8 is selected from the group consisting of C.sub.1 -C.sub.4 linear or branched alkyl substituted with 0-3 halogens on each carbon.

L12 ANSWER 94 OF 98 USPATFULL on STN
AN 96:118701 USPATFULL
TI Method of inactivation of viral and bacterial blood contaminants
IN Goodrich, Jr., Raymond P., Pasadena, CA, United States
Platz, Matthew S., Columbus, OH, United States
Yerram, Nagender, South Pasadena, CA, United States
Hackett, Roger W., Pasadena, CA, United States
van Borssum Waalkes, Marjan, Vernendaal, Netherlands
Williams-Hughes, Christine M., Sierra Madre, CA, United States
Wong, Victoria A., Cary, NC, United States
PA Credit Managers Association of California, Burbank, CA, United States (U.S. corporation)
PI US 5587490 19961224
AI US 1993-165305 19931210 (8)
RLI Continuation-in-part of Ser. No. US 1993-47749, filed on 14 Apr 1993 which is a continuation-in-part of Ser. No. US 1992-825691, filed on 27 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-685931, filed on 16 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-656254, filed on 15 Feb 1991, now abandoned And a continuation-in-part of Ser. No. US 1990-632277, filed on 20 Dec 1990, now abandoned which is a continuation-in-part of

Ser. No. US 1991-686334, filed on 16 Apr 1991, now abandoned And Ser. No. US 1990-510234, filed on 16 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Trinh, Ba Kim
LREP Swanson & Bratchun, LLC
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 2118
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound is provided for inactivating viral, bacterial or other contamination in cells, body fluids or fractions thereof. The compound comprises a psoralen with a single substituent that is either a quaternary phosphonium or ammonium moiety, and at least one substituent that is a halogen. The compound selectively binds to the contaminant, and upon activation by irradiation, damages the contaminant.

L12 ANSWER 95 OF 98 USPATFULL on STN
AN 95:58110 USPATFULL
TI Method of administering a biologically active substance
IN Bechgaard, Erik, Hellerup, Denmark
Gizurarson, Sveinbjorn, Keflavik, Iceland
Hjortkjaer, Rolf K., Humlebaer, Denmark
PA Bechgaard International Research and Development A/S, Hellerup, Denmark (non-U.S. corporation)
PI US 5428006 19950627
AI US 1993-151802 19931115 (8)
DCD 20120314
RLI Continuation of Ser. No. US 1993-71604, filed on 4 Jun 1993, now abandoned which is a continuation of Ser. No. US 1992-870893, filed on 20 Apr 1992, now abandoned which is a division of Ser. No. US 1991-696564, filed on 8 May 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Davenport, A. M.
LREP Evenson, McKeown, Edwards & Lenahan
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 1468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for administering a therapeutically effective amount of a biologically active substance to the circulatory system of a mammal including administering a pharmaceutical composition having a total volume of 1-1000 μl to a nasal mucosal membrane of the mammal, the pharmaceutical composition including the therapeutically effective amount of the biologically active substance dissolved or suspended in a volume of 1-1000 μl of a n-glycofurol-containing vehicle including at least one n-glycofurol represented by the formula: ##STR1## wherein n is from 1 to 8, so that upon administration of the pharmaceutical composition to the nasal mucosal membrane, absorption of the biologically active substance through the mucosal membrane and into the blood stream of the mammal rapidly takes place and thereby allows the biologically active substance to exert its therapeutic effect.

L12 ANSWER 96 OF 98 USPATFULL on STN
AN 95:45502 USPATFULL
TI Method of inactivation of viral and bacterial blood contaminants
IN Platz, Matthew S., Columbus, OH, United States
Goodrich, Jr., Raymond P., Pasadena, CA, United States
Yerram, Nagendar, South Pasadena, CA, United States

PA Cryopharm Corporation, Pasadena, CA, United States (U.S. corporation)
PI US 5418130 19950523
AI US 1993-91674 19930713 (8)
RLI Continuation-in-part of Ser. No. US 1993-47749, filed on 14 Apr 1993 which is a continuation-in-part of Ser. No. US 1992-825691, filed on 27 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-685931, filed on 16 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-656254, filed on 15 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-632277, filed on 20 Dec 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-510234, filed on 16 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Saucier, Sandra
LREP Swanson & Bratscuhn
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 2577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for inactivating viral and/or bacterial contamination in blood cellular matter, such as erythrocytes and platelets, or protein fractions. The cells or protein fractions are mixed with chemical sensitizers and irradiated with, for example, UV, visible, gamma or X-ray radiation. In particular, quaternary ammonium or phosphonium substituted, halo-psoralen compounds are described as being useful.

L12 ANSWER 97 OF 98 USPATFULL on STN
AN 95:22893 USPATFULL
TI Pharmaceutical preparation
IN Bechgaard, Erik, Hellerup, Denmark
Gizurarson, Sveinbjorn, Keflavik, Iceland
Hjortkjaer, Rolf K., Humlebaer, Denmark
PA Bechgaard International Research and Development A/S, Hellerup, Denmark (non-U.S. corporation)
PI US 5397771 19950314
AI US 1993-118683 19930910 (8)
RLI Continuation of Ser. No. US 1991-791651, filed on 14 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-696564, filed on 8 May 1991, now abandoned
PRAI DK 1990-1170 19900510
DK 1990-2075 19900830
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Wegner, Cantor, Mueller & Player
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 1854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical preparation for application of an effective amount of one or more biologically active substance(s) to a mucosal membrane of a mammal comprising an n-glycofurol represented by the formula I: ##STR1## wherein n is 1 to 4 in an amount from: 0.1-30% preferably 0.1-20% most preferably 1-15% in water, or in vegetable oil or n-ethylene glycol(s) represented by formula II:

H(OCH.sub.2 CH.sub.2).sub.p OH

wherein p is 2 to 8, or in a mixture thereof. Nasal administration of the preparation produces a high plasma concentration of the

pharmaceutically active substance(s) nearly as rapid as by i.v. administration.

L12 ANSWER 98 OF 98 USPATFULL on STN
AN 95:7690 USPATFULL
TI Solid porous unitary form comprising micro-particles and/or nano-particles, and its preparation
IN Courteille, Frederic, Cachan, France
Coutel, Anne, Antony, France
Lebreton, Guy, Gif-Sur-Yvette, France
Veillard, Michel, Sceaux, France
PA Farmalyoc, France (non-U.S. corporation)
PI US 5384124 19950124
AI US 1992-835012 19920212 (7)
RLI Continuation of Ser. No. US 1989-382286, filed on 20 Jul 1989, now abandoned
PRAI FR 1988-9864 19880721
DT Utility
FS Granted
EXNAM Primary Examiner: Lovering, Richard D.
LREP Morgan & Finnegan
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New solid, porous unitary form comprising micro-particles and/or nano-particles, made by lyophilization are useful for the administration of therapeutically active substances, nutrition agents, diagnostic agents or cosmetic agents.